# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

		For	m 10-Q	
$\boxtimes$	QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE S	SECURITIES EX	KCHANGE ACT OF 1934	
	FOR THE TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) O	-	ERIOD ENDED MARCH 31, 2024 TIES EXCHANGE ACT OF 1934	
	FOR THE TRA	ANSITION PERIO	DD FROM TO	
		Commission fil	e number 001-35647	
			C CORPORATION ant as specified in its charter)	I
	Delaware (State or other jurisdiction of incorporation or organization)			90-0224471 (IRS Employer Identification No.)
			Suite 700, Lehi, UT 84043 cutive offices, including zip code)	
			) 432-9000 s telephone number)	
			uant to Section 12(b) of the Act:	
	Common Stock, par value \$0.0001  Title of each class		LFVN ng Symbol(s)	The Nasdaq Stock Market LLC  Name of each exchange on which registered
				· · · · · · · · · · · · · · · · · · ·
	check mark whether the registrant (1) has filed all reports required to be filed by Section torts), and (2) has been subject to such filing requirements for the past 90 days. Yes $\boxtimes$		ecurities Exchange Act of 1934 during the pr	eceding 12 months (or for such shorter period that the registrant was required to
	check mark whether the registrant has submitted electronically every Interactive Data Filhe registrant was required to submit such files). Yes $\boxtimes$ No $\square$	le required to be sub	mitted pursuant to Rule 405 of Regulation S-	$\Gamma$ (§232.405 of this chapter) during the preceding 12 months (or for such shorter
	check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-eorting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.	accelerated filer, a sn	naller reporting company, or an emerging gro	wth company. See the definitions of "large accelerated filer," "accelerated filer,"
Large accele			Accelerated filer	
Non-acceler	rated filer Growth Company	⊠	Smaller reporting company	
0 0	ng growth company, indicate by check mark if the registrant has elected not to use the ex	_	riod for complying with any new or revised f	inancial accounting standards provided pursuant to Section 13(a) of the Exchang
Indicate by	check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Ex	change Act). Yes	l No ⊠	
The number	of shares outstanding of the issuer's common stock, par value \$0.0001 per share, as of N	May 1. 2024 was 12.	700.556.	
		., ,		

### CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q, in particular "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations," and the information incorporated by reference herein contains "forward-looking statements" (as such term is defined in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended). These statements, within involve risks and uncertainties, reflect our current expectations, intentions, or strategies regarding our possible future results of operations, performance, and achievements. Forward-looking statements include, without limitation: statements regarding future products or product development; statements regarding future selling, general and administrative costs and research and development spending; statements regarding the future performance of our network marketing efforts; statements regarding our expectations regarding ongoing litigation; statements regarding international growth; and statements regarding future financial performance, results of operations, capital expenditures and sufficiency of capital resources to fund our operating requirements. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and applicable rules of the Securities and Exchange Commission and common law.

These forward-looking statements may be identified in this report and the information incorporated by reference by words such as "anticipate," "could," "estimate," "expect," "intend," "plan," "predict," "project," "should" and similar terms and expressions, including references to assumptions and strategies. These statements reflect our current beliefs and are based on information currently available to us. Accordingly, these statements are subject to certain risks, uncertainties, and contingencies, which could cause our actual results, performance, or achievements to differ materially from those expressed in, or implied by, such statements.

The following factors are among those that may cause actual results to differ materially from our forward-looking statements:

- Inability to properly manage, motivate and retain our independent consultants (which we previously referred to as "distributors" in our prior filings) or to attract new customers and independent consultants on an ongoing basis;
- The widespread outbreak of an illness or communicable disease or any other public health crisis, similar to the recent COVID-19 pandemic, could adversely affect our business, results of operations and financial condition;
- Inability to protect against cyber security risks and to maintain the integrity of data;
- · Inability to manage existing markets, open new international markets or expand our operations;
- · Non-compliance by our independent consultants with applicable legal requirements or our policies and procedures, including making improper and/or illegal claims about our products or earnings opportunity;
- · Inability of new products and technological innovations to gain customer or independent consultant or market acceptance;
- · Our business and stock price may be adversely affected if our internal controls over financial reporting is not effective;
- · Inability to execute our product launch process due to increased pressure on our supply chain, information systems and management;
- Inability to appropriately manage our inventory;
- · Disruptions in our information technology systems;
- International trade or foreign exchange restrictions, increased tariffs, foreign currency exchange fluctuations;
- · Inability to raise additional capital or complete desired acquisitions;
- · Inability to comply with financial covenants imposed by our revolving line of credit and the impact of debt service obligations and restrictive debt covenants;
- Dependence upon a few products for revenue;
- · We may be unable to retain our existing consultant force or customer base or attract additional customers and/or independent consultants;
- Changes to the Company's independent consultant compensation plans;
- · High quality materials for our products may become difficult to obtain or expensive;

- · Improper actions by our independent consultants that violate laws or regulations could harm our business;
- Dependence on third parties to manufacture our products;
- · Disruptions to the transportation channels used to distribute our products;
- · We may be subject to a product recall;
- · Unfavorable publicity on our business or products;
- Risks related to Global Not For Resale programs;
- · Our direct selling program could be found to not be in compliance with current or newly adopted laws or regulations in various markets;
- · The impact of actions by activist stockholders;
- · Legal proceedings may be expensive and time consuming;
- · Strict government regulations on our business;
- · Regulations governing the production or marketing of our products;
- · Risk of investigatory and enforcement action;
- · Government authorities may question our tax positions or transfer pricing policies or change their laws in a manner that could increase our effective tax rate or otherwise harm our business;
- · Failure to comply with anti-corruption laws;
- Loss of or inability to attract key personnel;
- · We may be held responsible for certain taxes or assessments and other obligations relating to the activity of our independent consultants;
- · Competition in the dietary supplement and personal care markets;
- · Our inability to protect our intellectual property rights;
- · Third party claims that we infringe on their intellectual property;
- · Product liability claims against us;
- · Consumer discretionary spending habits factor into our economic success;
- · Economic, political, foreign exchange and other risks associated with international operations;
- Unfavorable global economic conditions, including high inflation, and other macroeconomic conditions;
- · Potential delisting of our common stock due to non-compliance with Nasdaq's continued listing requirements;
- · Volatility of the market price of our common stock; and
- · Substantial sales of shares may negatively impact the market price of our common stock.

When considering these forward-looking statements, you should keep in mind the cautionary statements in this report and the documents incorporated by reference. Except as required by law, we have no obligation and do not undertake to update or revise any such forward-looking statements to reflect events or circumstances after the date of this report.

# LIFEVANTAGE CORPORATION

# INDEX

		TAGE
PART I. Financial	1 Information	
Item 1.	Financial Statements:	<u>5</u>
	Condensed Consolidated Balance Sheets (unaudited)	5
	Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited)	<u>6</u>
	Condensed Consolidated Statement of Stockholders' Equity (unaudited)	7
	Condensed Consolidated Statements of Cash Flows (unaudited)	9
	Notes to Condensed Consolidated Financial Statements (unaudited)	<u>10</u>
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>19</u>
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	<u>26</u>
Item 4.	Controls and Procedures	27
DARTH O. I		2-
PART II. Other In		<u>27</u>
Item 1.	<u>Legal Proceedings</u>	<u>21</u>
Item 1A.	Risk Factors	<u>27</u>
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>27</u>
Item 3.	Defaults Upon Senior Securities	28
Item 4.	Mine Safety Disclosures	<u>28</u>
Item 5.	Other Information	<u>28</u>
Item 6.	Exhibits	<u>28</u>
Signatures		<u>30</u>

# PART I. Financial Information

# Item 1. Financial Statements

# LIFEVANTAGE CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

		March 31, 2024		June 30, 2023
(In thousands, except per share data)				
ASSETS				
Current assets				
Cash and cash equivalents	\$	17,377	\$	21,605
Accounts receivable		2,135		1,612
Income tax receivable		360		241
Inventory, net		15,162		16,073
Prepaid expenses and other		2,763		4,753
Total current assets		37,797		44,284
Property and equipment, net		8,349		9,086
Right-of-use assets		9,382		8,738
Intangible assets, net		356		455
Deferred income tax asset		4,927		2,991
Other long-term assets		496		569
TOTAL ASSETS	\$	61,307	\$	66,123
	-			
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current liabilities				
Accounts payable	\$	6,954	\$	3,505
Commissions payable		6,093		6,651
Income tax payable		772		_
Lease liabilities		1,675		1,521
Other accrued expenses		6,981		7,932
Total current liabilities		22,475		19,609
Long-term lease liabilities		11,852		11,566
Other long-term liabilities		211		299
Total liabilities		34,538		31,474
Commitments and contingencies - Note 7		34,336		31,474
Stockholders' equity				
Preferred stock — par value \$0.0001 per share, 5,000 shares authorized, no shares issued or outstanding		_		_
Common stock — par value \$0.0001 per share, 40,000 shares authorized and 12,688 and 12,622 issued and outstanding as of March 31, 2024 and June 30, 2023, respectively		1		1
Additional paid-in capital		136,198		134,314
Accumulated deficit		(107,709)		(98,305)
Accumulated other comprehensive loss		(1,721)		(1,361)
Total stockholders' equity		26,769		34,649
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	S	61,307	\$	66,123
TOTAL DELICITIES OF SCHOOL EQUIT	<u> </u>	01,307	¥	00,123

# LIFEVANTAGE CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited)

Three Months Ended March 31 Nine Months Ended March 31, (In thousands, except per share data) 151,233 \$ 159,177 Revenue, net \$ 48,245 \$ 53,741 \$ 10,172 10,618 31,418 32,318 Cost of sales Gross profit 119,815 126,859 Operating expenses: Commissions and incentives 19,714 23,816 63,941 71,185 Selling, general and administrative 16,425 17,708 54,452 54,018 Total operating expenses 36,139 41,524 118,393 125,203 Operating income 1,934 1,599 1,422 1,656 Other income (expense): 91 76 59 352 Interest income, net Other income (expense), net (135) (304) (89) Total other income (expense) (13) 66 (213) Income before income taxes 1,921 1,665 1,639 1,443 (7) 1,632 Income tax expense (262)(643) (869) 574 Net income 1,022 1,659 Net income per share: 0.13 \$ 0.08 \$ 0.13 \$ 0.05 Basic Diluted 0.13 0.08 0.13 \$ 0.05 Weighted-average shares outstanding: 12 424 12,615 12 525 12 538 Basic Diluted 12,986 12,770 13,010 12,555 Other comprehensive (loss) income, net of tax: Foreign currency translation adjustment Other comprehensive (loss) income, net of tax (529) \$ 14 \$ (360) \$ 144 144 (529)14 (360)Comprehensive income 1,036 718 1,130 1,272

# LIFEVANTAGE CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited)

_	Commo	on Stock	_	Additional Paid-In	Accumulated		Accumulated Other			
<u> </u>	Shares	Amount		Capital		Deficit		Comprehensive Loss		Total
(In thousands, except per share data)										
Balances, June 30, 2023	12,622	\$ 1	\$	134,314	\$	(98,305)	\$	(1,361)	\$	34,649
Stock-based compensation	_	_		978		_		_		978
Common stock issued under equity award plans	281									776
Shares canceled or surrendered as payment of tax withholding and other	(90)	_		(465)				_		(465)
Repurchase of company stock	(145)			(403)		(795)				(795)
Common stock issued under employee stock purchase plan	39	_		126		(175)		_		126
Cash dividends	_	_				(5,534)		_		(5,534)
Currency translation adjustment	_	_		_		(5,551)		(294)		(294)
Net income	_	_		_		629				629
Balances, September 30, 2023	12,707	§ 1	\$	134,953	\$	(104,005)	\$	(1,655)	\$	29,294
			_				_			
Stock-based compensation	_	_		750		_		_		750
Common stock issued under equity award plans	495	_		_		_		_		_
Shares canceled or surrendered as payment of tax withholding and other	(34)	_		(213)		_		_		(213)
Repurchase of company stock	(288)	_		_		(1,876)		_		(1,876)
Cash dividends	_	_		_		(455)		_		(455)
Currency translation adjustment	_	_		_		_		463		463
Net loss	_	_		_		(656)		_		(656)
Balances, December 31, 2023	12,880	\$ 1	\$	135,490	\$	(106,992)	\$	(1,192)	\$	27,307
_										
Stock-based compensation	_	_		796		_		_		796
Common stock issued under employee stock purchase plan	25	_		145		_		_		145
Common stock issued under equity award plans	113	_		_		_		_		_
Shares canceled or surrendered as payment of tax withholding and other	(38)	_		(233)		_		_		(233)
Repurchase of company stock	(292)	_		` <u> </u>		(1,928)		_		(1,928)
Cash dividends	` <u> </u>	_		_		(448)		_		(448)
Currency translation adjustment	_	_		_		_		(529)		(529)
Net income	_					1,659				1,659
Balances, March 31, 2024	12,688	\$ 1	\$	136,198	\$	(107,709)	\$	(1,721)	\$	26,769

# LIFEVANTAGE CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (CONTINUED) (Unaudited)

	Commo	n Stock	Amount		Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss	Total
(In thousands, except per share data)				_	·	_		_	<u> </u>	 -
Balances, June 30, 2022	12,493	\$	1	\$	131,075	\$	(98,437)	\$	(1,123)	\$ 31,516
Stock-based compensation	_		_		602		_		_	602
Common stock issued under equity award plans	48		_		_		_		_	_
Shares canceled or surrendered as payment of tax withholding and other	(17)		_		(72)		_		_	(72)
Common stock issued under employee stock purchase plan	36		_		121		_		_	121
Cash dividends	_		_		_		(377)		_	(377)
Currency translation adjustment	_		_		_		_		(510)	(510)
Net income	_		_		_		610		_	610
Balances, September 30, 2022	12,560	\$	1	\$	131,726	\$	(98,204)	\$	(1,633)	\$ 31,890
Stock-based compensation	_		_		823		_		_	823
Common stock issued under equity award plans	152		_		_		_		_	_
Shares canceled or surrendered as payment of tax withholding and other	(5)		_		(19)		_		_	(19)
Cash dividends	_		_		_		(381)		_	(381)
Currency translation adjustment	_		_		_		_		640	640
Net loss	_		_		_		(1,058)		_	(1,058)
Balances, December 31, 2022	12,707	\$	1	\$	132,530	\$	(99,643)	\$	(993)	\$ 31,895
Stock-based compensation	_		_		817		_		_	817
Common stock issued under employee stock purchase plan	40		_		131		_		_	131
Common stock issued under equity award plans	38		_		_		_		_	_
Shares canceled or surrendered as payment of tax withholding and other	(14)		_		(54)		_		_	(54)
Cash dividends	<u> </u>		_				(383)		_	(383)
Currency translation adjustment	_		_		_		` <u></u>		14	14
Net income	_		_		_		1,022		_	1,022
Balances, March 31, 2023	12,771	\$	1	\$	133,424	\$	(99,004)	\$	(979)	\$ 33,442

# LIFEVANTAGE CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

Temperature (Colspan="2")         1 (Colspan="2")	(Unaudited)			
Case Flows from Operating Activities:         S         1,622         S         5,74           Adjustments to reconcile net income to net cash provided by (used in) operating activities:         2,775         2,678           Depreciation and amortization         2,775         2,678           Stock-based compensation         2,275         2,242           Non-cash operating lease expense         92         1,257           Loss on disposal of seets         -         24           Deferred income tax         (1,95)         (53)           Changes in operating assets and liabilities:         (1,95)         975           Income tax receivable         (18)         1,900           Investigation of the company assets and subsection of the company assets and s				· /
Blows from Operating Activities:         \$         1,622         \$         5,74           Aljustments to reconcile net income to net eash provided by (used in) operating activities:         2,775         2,678           Stock-based compensation         2,524         2,242           Non-can operating lease expense         92         1,252           Loss on disposal of sexes         92         2,242           Deferred mome tax         (1,935)         95           Changes in operating assets and liabilities:         (1,935)         95           Accounts receivable         (118)         1,099           Income tax receivable         (183)         1,099           Inventory, net         1,933         1,589           Other long-term sexes         1,933         1,589           Other long-term sexes         3,385         (1,642)           Income tax payable         772         (453)           Other cancered expenses         1,525         3,385         (562)           Other cancered expenses         1,525         1,526         (3,385)         (1,642)           Income tax payable         772         (453)         (4,622)         (4,622)         (4,622)           Other cancered expenses         1,525         1,525	(1 d 1)		2024	2023
Net income	1			
Adjustments for reconcile net income to net cash provided by (used in) operating activities:   Depreciation and amortization   2,715   2,248   2,242   2,048		\$	1.622 \$	574
Depreciation and amortization   2,75		3	1,032 \$	3/4
Stock-based compensation         2,242         2,242           Non-cash operating lease expense         20         1,257           Loss on disposal of assets         (1,935)         263           Deferred income tax         (1,936)         303           Changes in operating assets and liabilities:         (185)         975           Income tax receivable         (188)         1,909           Inventory, net         725         (1,947)           Prepaid expenses and other         1,983         1,859           Other long-term assets         59         55           Accounts payable         772         (453)           Other accural expenses         (1,549)         (1,304)           Income tax payable         (1,549)         (1,304)           Other long-term liabilities         (1,100)         (1,274)           Other long-term liabilities         (1,100)         (1,274)           Net Cash Provided by Operating Activities         3,065         3,065           Cash Flows from Investing Activities         (1,967)         (2,554)           Net Cash Ived in Investing Activities         (1,967)         (2,554)           Repurchase of company stock         (4,599)            Cash Flows from Investing Activities <td></td> <td></td> <td>2 775</td> <td>2.679</td>			2 775	2.679
Non-cash operating lease expense   920   1.257   1.258   1.259   1.2				
Loss on disposal of assets   1,965   0,555     Deferred income tax				
Deferred income tax   Chapter in peratring assets and liabilities:   Accounts receivable   (552)   975   1,000   1,0			920	
Changes in operating assets and liabilities:         (552)         975           Accounts receivable         (118)         1,090           Inventory, net         725         (1,947)           Prepaid expenses and other         1,983         1,859           Other long-term assets         59         55           Accounts payable         3,385         (1,642)           Income tax payable         772         (433)           Other accrued expenses         (1,599)         (1,301)           Lease liabilities         115         (1,190)           Other long-term liabilities         115         (1,197)           Other long-term liabilities         9,615         3,665           Cast Flows from Investing Activities         115         (1,197)         (2,554)           Cast Flows from Investing Activities         (1,967)         (2,554)           Vet Cash Used in Investing Activities         (1,967)         (2,554)           Cast Flows from Financing Activities         (1,967)         (2,554)           Cast Flows from Financing Activities         (1,967)         (2,554)           Cast Listed in Investing Activities         (4,599)         -           Repurchase of company stock         (4,599)         -           P			(1.036)	
Accounts receivable         (552)         975           Income tax receivable         (118)         1,090           Inventory, net         725         (1,947)           Prepaid expenses and other         1,983         1,859           Other long-term assets         59         55           Accounts payable         3,385         (1,642)           Income tax payable         772         (453)           Other accrued expenses         (1,159)         (1,301)           Other carcued expenses         (1,120)         (1,274)           Other accrued expenses         (1,120)         (1,274)           Other cornel dayenese         (1,150)         (1,274)           Other long-term liabilities         151         (119)           Net Cash Provided by Operating Activities         9,615         3,065           Cash Flows from Investing Activities         (1,967)         (2,554)           Net Cash Used in Investing Activities         (1,967)         (2,554)           Net Cash Used in Investing Activities         (4,599)         -           Payment of cash dividends         (6,437)         (1,141)           Proceeds from common stock issued under employee stock purchase plan         (2,554)           Net Cash Used in Financing Activities <td></td> <td></td> <td>(1,530)</td> <td>(933)</td>			(1,530)	(933)
Income tax receivable   (118)   1,090     Inventory, net			(552)	075
Inventory, net				
Prepaid expenses and other         1,983         1,889           Other long-term assets         59         55           Accounts payable         3,385         1,642)           Income tax payable         772         (453)           Other accrued expenses         (1,549)         (1,301)           Lease liabilities         (1,120)         (1,271)           Other fong-term liabilities         115         (119)           Net Cash Provided by Operating Activities         9,615         3,065           Cash Flows from Investing Activities         (1,967)         (2,554)           Net Cash Used in Investing Activities         (1,967)         (2,554)           Net Cash Used in Investing Activities         (4,599)         —           Repurchase of company stock         (4,599)         —           Payment of cash dividends         (6,437)         (1,141)           Shares canceled or surrendered as payment of tax withholding and other         (911)         (145)           Proceeds from common stock issued under employee stock purchase plan         271         252           Net Cash Used in Financing Activities         (20)         (1,381)           Foreign Currency Effect on Cash         (20)         (138)           Decrease in Cash and Cash Equivalents— expeniming of				
Other long-term assets         59         55           Accounts payable         3,385         (1,642)           Other accrued expenses         (1,549)         (1,301)           Lease liabilities         (1,120)         (1,274)           Other non-term liabilities         115         (119)           Net Cash Provided by Operating Activities         9,615         3,065           Cash Flows from Investing Activities         (1,967)         (2,554)           Purchase of property and equipment         (1,967)         (2,554)           Net Cash Iwas from Financing Activities         (1,967)         (2,554)           Cash Flows from Financing Activities         (1,967)         (2,554)           Repurchase of company stock         (4,599)         -           Payment of cash dividends         (6,437)         (1,141)           Shares canceled or surrendered as payment of tax withholding and other         (6,437)         (1,141)           Proceeds from common stock issued under employee stock purchase plan         271         252           Net Cash Used in Financing Activities         (11,676)         (1,341)           Forcian Currency Effect on Cash         (200)         (1,341)           Forcian Currency Effect on Cash         (200)         (1,381)           Decre				
Accounts payable         3,385         (1,642)           Income tax payable         772         (453)           Other accrued expenses         (1,549)         (1,310)           Lease liabilities         (1,120)         (1,274)           Other long-term liabilities         (1,120)         (1,274)           Other long-term liabilities         9,615         3,065           Cash Frowfield by Operating Activities         (1,967)         (2,554)           Purchase of property and equipment         (1,967)         (2,554)           Ket Cash Used in Investing Activities         (1,967)         (2,554)           Cash Flows from Financing Activities         (1,967)         (2,554)           Repurchase of company stock         (6,437)         (1,141)           Shares canceled or surrendered as payment of tax withholding and other         (911)         (145)           Proceeds from common stock issued under employee stock purchase plan         271         252           Proceeds from common stock issued under employee stock purchase plan         (11,676)         (1,341)           Forigo Currency Effect on Cash         (200)         (138)           Decrease in Cash and Cash Equivalents         (2,00)         (138)           Cash and Cash Equivalents — beginning of period         21,065				
Income tax payable				
Other accrued expenses         (1,549)         (1,301)           Lease liabilities         (1,120)         (1,274)           Other long-term liabilities         115         (1,967)           Net Cash Provided by Operating Activities         9,615         3,065           Cash Flows from Investing Activities         (1,967)         (2,554)           Net Cash Used in Investing Activities         (1,967)         (2,554)           Cash Flows from Financing Activities         (1,967)         (2,554)           Cash Flows from Financing Activities         (4,599)         —           Payment of cash dividends         (6,437)         (1,141)           Shares canceled or surrendered as payment of tax withholding and other         (911)         (145)           Proceeds from common stock issued under employee stock purchase plan         271         252           Net Cash Used in Financing Activities         (11,676)         (1,034)           Proceeds from common stock issued under employee stock purchase plan         271         252           Net Cash Used in Financing Activities         (200)         (1,034)           Proceeds from common stock issued under employee stock purchase plan         271         252           Net Cash Used in Financing Activities         (200)         (1,034)           Early Cash Low				
Lease liabilities         (1,120)         (1,274)           Other long-term liabilities         115         (119)           Net Cash Provided by Operating Activities         9,615         3,635           Cash Flows from Investing Activities				( /
Other long-term liabilities         115         (119)           Net Cash Provided by Operating Activities         9,615         3,065           Cash Flows from Investing Activities         1,967         2,554           Purchase of property and equipment         (1,967)         (2,554)           Net Cash Used in Investing Activities         (1,967)         (2,554)           Cash Flows from Financing Activities         (4,599)         —           Repurchase of company stock         (6,437)         (1,141)           Shares canceled or surrendered as payment of tax withholding and other         (911)         (145)           Proceeds from common stock issued under employee stock purchase plan         271         252           Net Cash Used in Financing Activities         (11,676)         (1,034)           Foreign Currency Effect on Cash         (10,034)         (1,034)           Becrease in Cash and Cash Equivalents         (200)         (138)           Decrease in Cash and Cash Equivalents — beginning of period         21,605         20,106           Cash and Cash Equivalents— end of period         3         17,377         3         19,529           Cash and Cash Equivalents— end of period         5         3         3           Cash paid for interest         3         5         5				
Net Cash Provided by Operating Activities         9,615         3,065           Cash Flows from Investing Activities:         (1,967)         (2,554)           Net Cash Used in Investing Activities         (1,967)         (2,554)           Cash Flows from Financing Activities:         (1,967)         (2,554)           Repurchase of company stock         (4,599)         —           Payment of cash dividends         (6,437)         (1,141)           Shares canceled or surrendered as payment of tax withholding and other         (911)         (145)           Proceeds from common stock issued under employee stock purchase plan         271         252           Net Cash Used in Financing Activities         (11,676)         (1,034)           Foreign Currency Effect on Cash         (200)         (138)           Decrease in Cash and Cash Equivalents:         (200)         (138)           Cash and Cash Equivalents — beginning of period         21,605         20,100           Cash and Cash Equivalents — end of period         \$         17,377         \$         19,529           Cash paid for interest         \$         5         \$         3				
Cash Flows from Investing Activities           Purchase of property and equipment         (1,967)         (2,554)           Net Cash Used in Investing Activities         (1,967)         (2,554)           Cash Flows from Financing Activities         (4,599)         —           Repurchase of company stock         (6,437)         (1,141)           Shares canceled or surrendered as payment of tax withholding and other         (911)         (145)           Proceeds from common stock issued under employee stock purchase plan         271         252           Net Cash Used in Financing Activities         (11,676)         (1,034)           Foreign Currency Effect on Cash         (200)         (138)           Decrease in Cash and Cash Equivalents         (4,228)         (661)           Cash and Cash Equivalents—beginning of period         21,605         20,190           Cash and Cash Equivalents—end of period         5         19,529           Cash paid for interest         5         3				
Purchase of property and equipment         (1,967)         (2,554)           Net Cash Used in Investing Activities         (1,967)         (2,554)           Cash Flows from Financing Activities:         8         (4,599)         -           Repurchase of company stock         (6,437)         (1,141)           Shares canceled or surrendered as payment of tax withholding and other         (911)         (145)           Proceeds from common stock issued under employee stock purchase plan         271         252           Net Cash Used in Financing Activities         (11,676)         (1,034)           Foreign Currency Effect on Cash         (200)         (138)           Decrease in Cash and Cash Equivalents:         (4,228)         (661)           Cash and Cash Equivalents — beginning of period         21,605         20,100           Cash and Cash Equivalents—end of period         21,605         20,190           Cash and Cash Equivalents—end of period         5         19,529           Cash paid for interest         5         3         3			2,013	3,003
Net Cash Used in Investing Activities         (1,967)         (2,554)           Cash Flows from Financing Activities:         Repurchase of company stock         (4,599)         ———————————————————————————————————			(1.967)	(2.554)
Cash Flows from Financing Activities:         Repurchase of company stock       (4,599)       —         Payment of cash dividends       (6,437)       (1,141)         Shares canceled or surrendered as payment of tax withholding and other       (911)       (145)         Proceeds from common stock issued under employee stock purchase plan       271       252         Net Cash Used in Financing Activities       (11,676)       (1,034)         Foreign Currency Effect on Cash       (200)       (138)         Decrease in Cash and Cash Equivalents       (4,228)       (661)         Cash and Cash Equivalents — beginning of period       21,605       20,190         Cash and Cash Equivalents — end of period       \$       17,377       \$       19,529         SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION       \$       5       \$       3       3         Cash paid for interest       \$       5       \$       3       3				
Repurchase of company stock         (4,599)         —           Payment of cash dividends         (6,437)         (1,141)           Shares canceled or surrendered as payment of tax withholding and other         (911)         (145)           Proceeds from common stock issued under employee stock purchase plan         271         252           Net Cash Used in Financing Activities         (11,676)         (1,034)           Foreign Currency Effect on Cash         (200)         (138)           Decrease in Cash and Cash Equivalents         (4,228)         (661)           Cash and Cash Equivalents — beginning of period         21,605         20,190           SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION         5         17,377         5         19,529           Cash paid for interest         \$         5         5         \$         3			(1,507)	(2,334)
Payment of cash dividends         (6,437)         (1,141)           Shares canceled or surrendered as payment of tax withholding and other         (911)         (145)           Proceeds from common stock issued under employee stock purchase plan         271         252           Net Cash Used in Financing Activities         (11,676)         (1,034)           Foreign Currency Effect on Cash         (200)         (138)           Decrease in Cash and Cash Equivalents:         (4,228)         (661)           Cash and Cash Equivalents — beginning of period         21,605         20,190           Cash and Cash Equivalents — end of period         \$         17,377         9         19,529           SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION         \$         5         5         3			(4 599)	_
Shares canceled or surrendered as payment of tax withholding and other         (91)         (145)           Proceeds from common stock issued under employee stock purchase plan         271         252           Net Cash Used in Financing Activities         (11,676)         (1,034)           Foreign Currency Effect on Cash         (200)         (138)           Decrease in Cash and Cash Equivalents:         (4,228)         (661)           Cash and Cash Equivalents — beginning of period         21,605         20,190           Cash and Cash Equivalent — end of period         \$         17,377         \$         19,529           SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION         \$         5         \$         3         3           Cash paid for interest         \$         5         \$         3         3				
Proceeds from common stock issued under employee stock purchase plan         271         252           Net Cash Used in Financing Activities         (11,676)         (1,034)           Foreign Currency Effect on Cash         (200)         (138)           Decrease in Cash and Cash Equivalents         (4,228)         (661)           Cash and Cash Equivalents — beginning of period         21,605         20,190           Cash and Cash Equivalents — end of period         5         17,377         9         19,529           SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION         S         5         3         3				
Net Cash Used in Financing Activities         (11,676)         (1,034)           Foreign Currency Effect on Cash         (200)         (138)           Decrease in Cash and Cash Equivalents:         (4,228)         (661)           Cash and Cash Equivalents – beginning of period         21,605         20,190           Cash and Cash Equivalents – end of period         \$ 17,377         \$ 19,529           SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION         \$ 5         \$ 3				
Foreign Currency Effect on Cash         (200)         (138)           Decrease in Cash and Cash Equivalents:         (4,228)         (661)           Cash and Cash Equivalents — beginning of period         21,605         20,190           Cash and Cash Equivalents — end of period         5         17,377         9           SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION         5         5         3           Cash paid for interest         \$         5         \$         3				
Decrease in Cash and Cash Equivalents:         (4,228)         (661)           Cash and Cash Equivalents — beginning of period         21,605         20,190           Cash and Cash Equivalents — end of period         \$ 17,377         \$ 19,529           SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION         \$ 5         \$ 3           Cash paid for interest         \$ 5         \$ 3	· · · · · · · · · · · · · · · · · · ·		( ' '	
Cash and Cash Equivalents — beginning of period         21,605         20,190           Cash and Cash Equivalents — end of period         \$ 17,377         \$ 19,529           SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION           Cash paid for interest         \$ 5         \$ 3				
Cash and Cash Equivalents — end of period  SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION  Cash paid for interest  \$ 5 \$ 3				
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION  Cash paid for interest  \$ 5 \$ 3		<u>e</u>		
Cash paid for interest \$ 5 \$ 3		<del>g</del>	11,577	17,327
		\$	5 \$	3
	Cash paid for income taxes	S	1,381 \$	977

# LIFEVANTAGE CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes of LifeVantage Corporation ("LifeVantage" or the "Company") as of and for the year ended June 30, 2023 included in the annual report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on August 28, 2023.

### Note 1 — Organization and Basis of Presentation

LifeVantage is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company is dedicated to helping people achieve their health, wellness and financial goals. The Company provides quality, scientifically-validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to its independent consultants. LifeVantage sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The Company sold its products in China through a China approved cross-border e-commerce business model until March 15, 2023, at which time the Company closed its e-commerce business in China.

The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath & body, and targeted relief products. The Company's line of scientifically validated dietary supplements includes its flagship Protandim® family of products, LifeVantage® Omega+, ProBio, IC Bright®, Daily Wellness, Rise AM, Reset PM and D3+ dietary supplements. TrueScience® is the Company's NrI2 enhanced line of skin, hair, and bath & body products. The Company also markets and sells Petandim®, its companion pet supplement formulated to combat oxidative stress in dogs, AXIO® its nootropic energy drink mixes, and PhysIQ™, its smart weight management system.

The condensed consolidated financial statements included herein have been prepared by the Company's management, without audit, pursuant to the rules and regulations of the SEC. In the opinion of the Company's management, these interim financial statements include all adjustments that are considered necessary for a fair presentation of its financial position as of March 31, 2024, and the results of operation 2024 and 2023, and the cash flows for the nine months ended March 31, 2024 and 2023. Interim results are not necessarily indicative of results for a full year or for any future period. sary for a fair presentation of its financial position as of March 31, 2024, and the results of operations for the three and nine months ended March 31,

The condensed consolidated financial statements and notes included herein are presented as required by Form 10-Q, and do not contain certain information included in the Company's audited financial statements and notes for the fiscal year ended June 30, 2023, pursuant to the rules and regulations of the SEC. For further information, refer to the financial statements and notes thereto as of and for the year ended June 30, 2023, and included in the annual report on Form 10-K on file with the SEC.

### Note 2 - Summary of Significant Accounting Policies

### Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation.

The Company prepares the condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America ("GAAP"). In preparing these statements, the Company is required to use estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates and assumptions. On an ongoing basis, the Company reviews its estimates, including, but not limited to, those related to inventory valuation and obsolescence, sales returns, income taxes and tax valuation reserves, transfer pricing methodology and positions, impairment of assets, share-based compensation, and loss contingencies.

### Foreign Currency Translation

A portion of the Company's business operations occurs outside the United States. The local currency of each of the Company's subsidiaries is generally its functional currency. All assets and liabilities are translated into U.S. dollars at exchange rates existing at the balance sheet dates, revenue and expenses are translated at weighted-average exchange rates and

stockholders' equity is recorded at historical exchange rates. The resulting foreign currency translation adjustments are recorded as a separate component of stockholders' equity in the condensed consolidated balance sheets and as a component of comprehensive income. Transaction gains and losses are included in other expense, net in the condensed consolidated statements of operations and comprehensive income. For the three months ended March 31, 2024 and 2023, net foreign currency losses of \$0.1 million and gains of \$36,000, respectively, are recorded in other income (expense), net. For the nine months ended March 31, 2024 and 2023, net foreign currency losses of \$0.2 million and \$0.2 million, respectively, are recorded in other income (expense), net.

### Cash and Cash Equivalents

The Company considers only its monetary liquid assets with original maturities of three months or less as cash and cash equivalents.

### Concentration of Credit Risk

Accounting guidance for financial instruments requires disclosure of significant concentrations of credit risk regardless of the degree of such risk. Financial instruments with significant credit risk include cash and investments. At March 31, 2024, the Company had \$13.1 million in cash accounts at one financial institution and \$4.3 million in accounts at other financial institutions. At June 30, 2023, the Company had \$17.0 million in cash accounts at one financial institution and \$4.6 million in accounts at other financial institutions. As of March 31, 2024 and June 30, 2023, and during the periods then ended, the Company's cash balances exceeded federally insured limits.

### Accounts Receivable

The Company's accounts receivable as of March 31, 2024 and June 30, 2023 consist primarily of credit card receivables. Based on the Company's verification process for customer credit cards and historical information available, management has determined that an allowance for doubtful accounts on credit card sales related to its customer sales as of March 31, 2024 and June 30, 2023 is not necessary. No bad debt expense was recorded during the three and nine months ended March 31, 2024 and 2023.

### Inventory

As of March 31, 2024 and June 30, 2023, inventory consisted of (in thousands):

		March 31, 2024		ine 30, 2023
Finished goods	\$ 11,27	3 74.4 %	\$ 12,153	75.6 %
Raw materials	3,88	9 25.6 %	3,920	24.4 %
Total inventory	\$ 15,16	2 100.0 %	\$ 16,073	100.0 %

Inventories are carried at the lower of cost or net realizable value, using the first-in, first-out method, which includes a reduction in inventory values of \$1.3 million and \$1.3 million at March 31, 2024 and June 30, 2023, respectively, related to obsolete and slow-moving inventory.

### Fair Value of Financial Instruments

The Company accounts for assets and liabilities using a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. These two types of inputs have created the fair-value hierarchy below. This hierarchy requires the Company to minimize the use of unobservable inputs and to use observable market data, if available, when determining fair value.

- Level 1—Quoted prices for identical instruments in active markets;
- Level 2—Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and
- · Level 3—Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Our financial instruments, consisting primarily of cash and cash equivalents, accounts receivable, and accounts payable, approximate fair value due to their short-term nature.

### Revenue Recognition

Revenue is recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales, value-added, and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue

The Company generates the majority of its revenue through product sales to customers. These products include the Protandim® line of dietary supplements, LifeVantage® Omega+, ProBio, IC Bright®, Daily Wellness, Rise AM, Reset PM, and D3+ dietary supplements, TrueScience® skin, hair, bath & body and targeted relief, Petandim®, Axio® nootropic energy drink mixes, and the PhysIQ $^{\text{TM}}$  smart weight management system. The Company ships most of its umer and receives substantially all payment for product sales in the form of credit card receipts. Revenue from direct product sales to customers is recognized upon shipment, which is when passage of title and risk of loss occurs. For items sold in packs and bundles, the Company determines the standalone selling price at contract inception for each distinct good, and then allocates the transaction price on a relative standalone selling price basis. Any discounts are accounted for as a direct reduction to the transaction price. Shipping and handling revenue is recognized upon shipment when the performance obligation is completed

Contract liabilities, recorded as deferred revenue, include lovalty program credit deferrals with certain customers which are accounted for as a reduction in the transaction price and are generally recognized as credits which are redeemed for additional products at a later date. The Company also records deferred revenue when cash payments are received or due in advance of performance, including amounts which are refundable. In addition, the Company presells tickets to its events. When cash payments are received in advance of events, the cash received is recorded to deferred revenue until the event is held, at which time the Company has performed its obligations under the contract and

Deferred revenue is included in accrued expenses in the consolidated balance sheets. The balance of deferred revenue related to contract liabilities was \$0.7 million and \$0.8 million as of March 31, 2024 and June 30, 2023, respectively. The contract liabilities impact to revenue for the three months ended March 31, 2024 and 2023 was an increase of \$0.2 million and a decrease of \$0.1 million, respectively. The contract liabilities impact to revenue for the nine months ended March 31, 2024 and 2023 was an increase of \$0.1 million and a decrease of \$0.3 million, respectively.

Estimated returns are recorded when product is shipped. Subject to some exceptions based on local regulations, the Company's return policy is to provide a full refund for product returned within 30 days. After 30 days of purchase, only unopened product that is in a resalable and restockable condition may be returned within twelve months of purchase and shall receive a 100% refund, less a 10% handling and restocking fee and any shipping and handling costs. The Company establishes a refund liability reserve, and an asset reserve for its right to recover products, based on historical experience. The returns asset reserve and returns liability reserve are evaluated on a quarterly basis. As of March 31, 2024 and June 30, 2023, the returns liability reserve, net was \$0.1 million and \$0.1 million, respectively.

Shipping and handling costs associated with inbound freight and freight out to customers and independent consultants are included in cost of sales. Shipping and handling fees charged to customers and independent consultants are included in revenue.

## Research and Development Costs

The Company expenses all costs related to research and development activities, as incurred. Research and development expenses for the three months ended March 31, 2024 and 2023 were \$0.2 million and \$0.2 million, respectively. Research and development expenses for the nine months ended March 31, 2024 and 2023 were \$0.5 million and \$0.4 million, respectively.

The Company accounts for leases in accordance with Accounting Standards Codification ("ASC") 842. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are included in right-of-use ("ROU") assets, current lease liabilities and long-term lease liabilities on the condensed consolidated balance sheets. The Company does not have any finance leases.

Operating lease ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company's lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum

lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company's lease agreements do not contain any residual value guarantees.

Changes in the Company's strategies have resulted in operation modifications in certain Asia/Pacific markets resulting in the closure of showrooms and changes to selling models. As of December 31, 2022, the Company abandoned the ROU assets related to the Hong Kong and Singapore showroom leases. These leases were terminated in February 2023 and the Company has no remaining lease liability for these showrooms. Total expenses related to the abandonment of the ROU assets and costs associated with the change in operations in these markets for the nine months ended March 31, 2023 was \$0.4 million and is included in selling, general, and administrative expenses.

### Stock-Rosed Compensation

The Company recognizes stock-based compensation by measuring the cost of services to be rendered based on the grant date fair value of the equity award. The Company recognizes stock-based compensation, net of any estimated forfeitures, over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period. The Company estimates forfeitures based on historical information and other management assumptions. For awards with market-based performance conditions, the cost of the awards is recognized as the requisite service is rendered by employees, regardless of when, if ever, the market-based performance conditions are satisfied.

The Black-Scholes option pricing model is used to estimate the fair value of stock options and options under the Company's 2019 Employee Stock Purchase Plan. The determination of the fair value of options is affected by the Company's stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company uses historical data for estimating the expected volatility and expected life of stock options required in the Black-Scholes model. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the stock options.

The fair value of restricted stock grants, including performance restricted stock units that include non-market based performance conditions, is based on the closing market price of the Company's stock on the date of grant less the Company's expected dividend yield. The Company recognizes compensation costs for awards with performance conditions when it concludes it is probable that the performance conditions will be achieved. The Company reassesses the probability of vesting at each balance sheet date and adjusts compensation costs accordingly.

### Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled, updated as needed for changes in corporate tax rates. The effect on deferred tax assets and liabilities from a change in tax rates is recognized in income in the period that includes the effective date of the change. The Company recognizes tax liabilities or benefits from an uncertain position only if it is more likely than not that the position will be sustained upon examination by taxing authorities based on the technical merits of the issue. The amount recognized would be the largest liability or benefit that the Company believes has greater than a 50% likelihood of being realized upon settlement.

For the nine months ended March 31, 2024 and 2023, the Company recognized income tax expense of \$7,000 and \$0.9 million, respectively, which is reflective of the Company's current estimated federal, state and foreign effective tax rate. Realization of deferred tax assets is dependent upon future earnings in specific tax jurisdictions, the timing and amount of which are uncertain.

### Income Per Share

Basic income per common share is computed by dividing the net income by the weighted-average number of common shares outstanding during the period, less unvested restricted stock awards. Diluted income per common share is computed by dividing net income by the weighted-average common shares and potentially dilutive common share equivalents using the treasury stock method.

For the three months ended March 31, 2024 and 2023, the effects of approximately 8,000 and 0.1 million common shares, respectively, issuable upon exercise of options and non-vested shares of restricted stock are not included in computations as their effect was anti-dilutive. For the nine months ended March 31, 2024 and 2023, the effects of approximately 34,000 and 0.3 million common shares, respectively, issuable upon exercise of options and non-vested shares of restricted stock are not included in computations as their effect was anti-dilutive.

The following is a reconciliation of net income per share and the weighted-average common shares outstanding for purposes of computing basic and diluted net income per share (in thousands, except per share amounts):

		Three Months Ended March 31,				Nine Months Ended March 31,			
	20	2024		2023	20	024	2023		
Numerator:									
Net income	\$	1,659	\$	1,022	\$	1,632	\$	574	
Denominator:									
Basic weighted-average common shares outstanding		12,424		12,615		12,525		12,538	
Effect of dilutive securities:									
Stock awards and options		562		155		485		17	
Diluted weighted-average common shares outstanding		12,986		12,770		13,010		12,555	
Net income per share, basic	\$	0.13	\$	0.08	\$	0.13	\$	0.05	
Net income per share, diluted	\$	0.13	\$	0.08	\$	0.13	\$	0.05	

## Segment Information and Disaggregated Revenue

The Company operates in a single operating segment by selling products directly to customers and through an international network of independent consultants that operates in an integrated manner from market to market. Commissions and incentives expenses are the Company's largest expense comprised of the commissions paid to its independent consultants. The Company manages its business primarily by managing its international network of independent consultants. The Company disaggregates revenue in two geographic regions: the Americas region and the Asia/Pacific & Europe region.

The following table presents the Company's revenue disaggregated by these two geographic regions (in thousands):

The following table presents the company's revenue disaggregated by these two geographic regions (in	Three Months Ended March 31,					Nine Months Ended March 31,				
	20	024		2023		2024		2023		
Americas	\$	37,215	\$	39,532	\$	114,795	\$	115,606		
Asia/Pacific & Europe		11,030		14,209		36,438		43,571		
Total revenue	\$	48,245	\$	53,741	\$	151,233	\$	159,177		

Additional information as to the Company's revenue from operations in the most significant geographical areas is set forth below (in thousands):

		Three Months Ended March 31,					Nine Months Ended March 31,				
	2024			2023		2024		2023			
United States	\$	35,333	\$	37,855	\$	109,448	\$	110,485			
Japan	\$	6,223	\$	8,133	\$	21,051	\$	23,665			

The following table presents the Company's long-lived assets for its most significant geographic markets (in thousands):

United States	2024	2023		
United States	\$ 20,468	\$ 20,504		
Japan	\$ 2,156	\$ 354		

Manak 21

### Note 3 — Leases

The Company has operating leases for current corporate offices and certain equipment. These leases have remaining terms of approximately one to eight years. As of March 31, 2024, the weighted average remaining lease term and weighted average discount rate for operating leases was 7.28 years and 3.26%, respectively. As of June 30, 2023, the weighted average remaining lease term and weighted average discount rate for operating leases was 8.27 years and 3.25%, respectively.

For the three months ended March 31, 2024 and 2023, operating lease expense was \$0.5 million and \$0.6 million, respectively. For the nine months ended March 31, 2024 and 2023, operating lease expense was \$1.6 million and \$2.2 million, respectively.

The components of lease expense for the three and nine months ended March 31, 2024 and 2023, were as follows:

	Three Months Ended March 31,				Nine Months Ended March 31,			
	 2024		2023		2024		2023	
Operating lease expense								
Operating lease cost	\$ 459	\$	516	\$	1,451	\$	1,929	
Variable lease cost	42		103		136		189	
Short-term lease costs	12		18		35		63	
Total lease expense	\$ 513	\$	637	\$	1,622	\$	2,181	

Supplemental cash flow information related to operating leases was as follows (in thousands):

	Tillet Monthly Ended March 51,						
	2024		2023		2024		2023
Operating cash outflows from operating leases	\$ 560	\$	782	\$	1,651	\$	2,288
Right-of-use assets obtained in exchange for lease obligations	\$ 265	\$	_	\$	1,767	\$	_

Three Months Ended March 31

Nine Months Ended March 31

Maturity of lease liabilities at March 31, 2024 are as follows (in thousands):

Year ended June 30,	Ar	mount
2024 (remaining three months ending June 30, 2024)	\$	550
2025		2,025
2026		2,068
2027		2,080
2028		2,057
Thereafter		6,394
Total		15,174
Less: imputed interest		(1,647)
Present value of lease liabilities	\$	13,527

# Note 4 — Long-Term Debt

On March 30, 2016, the Company entered into a loan agreement (the "2016 Loan Agreement") and a security agreement (the "Security Agreement"). The 2016 Loan Agreement provides for a term loan in an aggregate principal amount of \$10.0 million (the "2016 Term Loan,") and a revolving loan facility in an aggregate principal amount not to exceed \$2.0 million (the "2016 Revolving Loan," and collectively with the 2016 Term Loan, the 2016 Loan Agreement and the Security Agreement, the "2016 Credit Facility" and together with the amendments described below, the "Credit Facility"). During the fiscal year ended June 30, 2020, the Company repaid, in full, the balance of the 2016 Term Loan.

On May 4, 2018 and February 1, 2019, the Company entered into loan modification agreements ("Amendment No. 1" and "Amendment No. 2", respectively). These loan modification agreements amended certain financial covenants and the available borrowing amount under the 2016 Revolving Loan.

On April 1, 2021, the Company entered into a loan modification agreement ("Amendment No. 3"), which amended the Credit Facility. Amendment No. 3, with an available borrowing amount of \$5.0 million, a revised maturity date from March 31, 2021 to March 31, 2024, and a modified variable interest rate based on the one-month United States Treasury Rate, plus a margin of 3.00%, with an interest rate floor of 4.00%. Amendment No. 3 also revised the debt (total liabilities) to tangible net worth ratio (as defined in Amendment No. 3) covenant to require that the Company maintain this ratio not in excess of 2.00 to 1.00, measured as of the end of each fiscal quarter, and revised the definition and calculation of the minimum fixed charge coverage ratio (as defined in Amendment No. 3). There were no other changes to the minimum fixed charge coverage ratio of 1.10 to 1.00 or the minimum working capital of \$6.0 million as set forth in previous amendments.

The Company entered into a loan modification agreement ("Amendment No. 4"), effective September 30, 2022, which further amended the Credit Facility. Amendment No. 4 revised the calculation of the minimum fixed charge coverage ratio (as defined in Amendment No. 4) and allows the Company to declare and pay dividends, up to \$500,000 per quarter, through September 30, 2023. There were no other changes to the covenants or revolving loan facility as set forth in Amendment No. 3.

If the Company borrows under the 2016 Revolving Loan, interest will be payable quarterly in arrears on the last day of each fiscal quarter.

On August 28, 2023, the Company received approval, without modifying Amendment No. 4, to declare and pay a one-time cash dividend of \$0.40 per share of common stock, to be paid on September 22, 2023. The Company also received approval to declare and pay dividends, up to \$750,000, per quarter, through September 30, 2024.

On March 31, 2024, the Credit Facility reached the maturity date and was terminated. As of March 31, 2024, there was no balance outstanding on this credit facility.

On April 12, 2024, the Company entered into a Loan Agreement (the "Loan Agreement") with Bank of America, N.A., as Lender (the "Lender"). In connection with the Loan Agreement and on the same date, the Company, Lifeline Nutraceuticals Corporation, as Guarantor (the "Guarantor"), and the Lender also entered into a Continuing and Unconditional Guaranty (the "Continuing and Unconditional Guaranty") and a Security and Pledge Agreement (the "Security and Pledge Agreement"). The Loan Agreement provides for a revolving line of credit in an aggregate principal amount not to exceed \$5.0 million (the "Line of Credit" and collectively with the Loan Agreement, Continuing and Unconditional Guaranty and the Security and Pledge Agreement the "2024 Credit Facility") (see Note 8 "Subsequent Events") for more details).

### Note 5 — Stockholders' Equity

During the three months ended March 31, 2024 and 2023, the Company issued 0.1 million and 38,000 shares of common stock, respectively, under equity award plans. During the three months ended March 31, 2024 and 2023, the Company issued zero shares of common stock upon the exercise of stock options. During the three months ended March 31, 2024 and 2023, 38,000 and 14,000 shares of restricted stock, respectively, were canceled or surrendered as payment of tax withholding upon vesting.

During the nine months ended March 31, 2024 and 2023, the Company issued 0.9 million and 0.2 million shares of common stock, respectively, under equity award plans. During the nine months ended March 31, 2024 and 2023, the Company issued zero shares of common stock upon the exercise of stock options. During the nine months ended March 31, 2024 and 2023, 0.2 million and 36,000 shares of restricted stock, respectively, were canceled or surrendered as payment of tax withholding upon vesting.

On November 27, 2017, the Company announced a share repurchase program authorizing it to repurchase up to \$5 million in shares of the Company's common stock. The repurchase program permits the Company to purchase shares through a variety of methods, including in the open market, through privately negotiated transactions or other means as determined by the Company's management. As part of the repurchase program, the Company has entered into a pre-arranged stock repurchase plan which operates in accordance with guidelines specified under Rule 1065-1 of the Securities Exchange Act of 1934, as amended. Accordingly, any transactions under such stock repurchase plan will be completed in accordance with the terms of the plan, including specified price, volume and timing conditions. The authorization may be suspended or discontinued at any time. On February 1, 2019, the Company's board of directors (the "Board of Directors") approved an amendment to increase the authorized share repurchase amount from \$15.0 million to \$35.0 million to \$35.0 million to \$35.0 million and to extend the duration of the program through November 30, 2023 and, on February 17, 2022, the Board of Directors approved an amendment to increase the authorized share repurchase amount from \$35.0 million. On June 12, 2023, the Board of Directors approved an amendment to extend the duration of the repurchase program period to December 31, 2026. During the three and nine months ended March 31, 2024, the Company purchased 0.3 million shares of common stock at an aggregate price of \$1.9 million and \$4.6 million under this repurchase program, respectively. During the three and nine months ended March 31, 2023, the Company purchased no shares of common stock under this repurchase program, respectively. At March 31, 2024, there is \$22.3 million remaining under this repurchase program.

On August 30, 2023, the Board of Directors approved a stockholder rights agreement (the "Rights Plan") and declared a dividend of one right for each outstanding share of common stock to stockholders of record on September 11, 2023. Each right entitles holders to purchase one newly issued share of preferred stock at an exercise price of \$20 per right, subject to adjustment. Initially, the rights are not exercisable and trade with shares of the Company's common stock

In general, the rights become exercisable following a public announcement that a person acquires 12% (or, in the case of passive investors, 20%) or more of the outstanding shares of the Company's common stock. If a person becomes an acquiring person, each holder of rights (except the acquiring person) will have the right to purchase, for the purchase price, a number of shares of the Company's common stock at a 50% discount to the then-current trading price. Rather than allowing the rights to be exercised in those circumstances, the Board of Directors may exchange each right, other than the rights owned by the acquiring person, for a share of the Company's common stock. The agreement provides for exceptions and additional terms for other certain situations and circumstances.

The Rights Plan is intended to protect the interests of LifeVantage and its stockholders by reducing the likelihood that any entity, person or group gains control of the Company through open-market accumulation or other means without payment of an adequate control premium and expires August 24, 2024, unless it is earlier terminated or the rights are earlier redeemed or exchanged by the Board of Directors. There is currently no impact to the Company's Consolidated Financial Statements

The Company's Certificate of Incorporation authorizes the issuance of preferred stock. However, as of March 31, 2024, none have been issued nor have any rights or preferences been assigned to the preferred stock by the Company's Board of Directors.

Dividand

In August 2023, the Board of Directors declared a quarterly cash dividend of \$0.035 per share of common stock and a one-time cash dividend of \$0.40 per share of common stock to be paid on September 22, 2023 to stockholders of record on September 8, 2023. In November 2023, the Board of Directors declared a quarterly cash dividend of \$0.035 per share of common stock to be paid on December 15, 2023 to stockholders of record on December 1, 2023. In January 2024, the Board of Directors declared a quarterly cash dividend of \$0.035 per share of common stock to be paid on March 15, 2024 to stockholders of record on March 1, 2024. Cash dividends for the three and nine months ended March 31, 2024 totaled \$0.4 million and \$6.4 million, or \$0.035 and \$0.51 per share, respectively. Cash dividends for the three and nine months ended March 31, 2023 totaled \$0.4 million and \$1.1 million, or \$0.03 and \$0.09 per share, respectively.

The declaration of dividends is subject to the discretion of the Board of Directors and will depend upon various factors, including the Company's earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by the Board of Directors.

### Note 6 - Stock-Based Compensation

# Long-Term Incentive Plans

### **Equity-Settled Plans**

The Company adopted, and the stockholders approved, the 2017 Long-Term Incentive Plan (the "2017 Plan"), effective February 16, 2017, to provide incentives to eligible employees, directors and consultants. The initial share pool approved was 650,000 shares. On November 9, 2023, the stockholders approved amendments to the 2017 Plan to increase the number of shares of the Company's common stock that are available for issuance under the 2017 plan by 1,138,000 shares. As of March 31, 2024, a maximum of 5.1 million shares of the Company's common stock can be issued under the 2017 Plan in connection with the grant of awards which is calculated as the sum of (i) 4,630,000 shares and (ii) up to 475,000 shares previously reserved for issuance under the Company's 2010 Long Term Incentive Plan, including shares returned upon cancellation, termination or forfeiture of awards that were previously granted under that plan. Outstanding stock options awarded under the 2017 Plan have exercise prices of \$4.44 per share, and vest over a three year vesting period. Awards expire in accordance with the terms of each award and, upon expiration of the award, the shares subject to the award are added back to the 2017 Plan. The contractual term of stock options granted is generally ten years. As of March 31, 2024, under the 2017 Plan, there were stock option awards outstanding, net of awards expired, for an aggregate of 0.1 million shares of the Company's common stock.

### Employee Stock Purchase Plan

General. The Company's 2019 Employee Stock Purchase Plan ("ESPP") was adopted by the Board of Directors in September 2018 and the Company's stockholders approved it in November 2018. The ESPP is intended to qualify under Section 423 of the Internal Revenue Code.

Share Reserve. The Company has reserved 0.4 million shares of its common stock for issuance under the ESPP. As of March 31, 2024, 0.1 million shares were available for issuance. The number of shares reserved under the ESPP will automatically be adjusted in the event of a stock split, stock dividend or a reverse stock split (including an adjustment to the per-purchase period share limit).

Purchase Price. Employees may purchase each share of common stock under the ESPP at a price equal to 85% of the lower of the fair market values of the stock as of the beginning or the end of the six-month offering periods. An employee's contributions to the ESPP are limited to 15% of their regular hourly or salary compensation, and up to a maximum of 3,000 shares may be purchased during any offering period. A participant shall not be granted an option under the ESPP if such option would permit the participant's rights to purchase stock to accrue at a rate exceeding \$25,000 grant date fair market value of stock for each calendar year in which such option is outstanding at any time.

Offering Periods. Unless otherwise determined by the compensation committee, the ESPP will be operated through a series of successive six-month offering periods, which will begin each year on March 1 and September 1.

During the three months ended March 31, 2024 and 2023, approximately 25,000 and 40,000 shares of common stock were issued under the ESPP, respectively. During the nine months ended March 31, 2024 and 2023, approximately 64,000 and 76,000 shares of common stock were issued under the ESPP, respectively.

### Stock-Based Compensation

For the three months ended March 31, 2024 and 2023, compensation of \$0.8 million and \$0.8 million, respectively, was reflected as an increase to additional paid-in capital, all of which was employee related. For the nine months ended March 31, 2024 and 2023, compensation of \$2.5 million and \$2.2 million, respectively, was reflected as an increase to additional paid-in capital, all of which was employee related.

## Note 7 — Commitments and Contingencies

### Contingencies

The Company accounts for contingent liabilities in accordance with ASC 450, Contingencies. This guidance requires management to assess potential contingent liabilities that may exist as of the date of the financial statements to determine the probability and amount of loss that may have occurred, which inherently involves an exercise of judgment. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. For loss contingencies considered remote, no accrual or disclosures are generally made. Management has assessed potential contingent liabilities as of March 31, 2024, and based on the assessment, there are no probable loss contingencies requiring accrual or disclosures within its financial statements.

### Legal Accruals

In addition to commitments and obligations in the ordinary course of business, from time to time, the Company is subject to various claims, pending and potential legal actions, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of its business. Management assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because evaluating legal claims and litigation results are inherently unpredictable and unfavorable results could occur, assessing contingencies is highly subjective and requires judgments about future events. When evaluating contingencies, management may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed or asserted against the Company may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of a potential liability. Management regularly reviews contingencies to determine the adequacy of financial statement accruals and related disclosures. The amount of ultimate loss may differ from these estimates. It is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable publicity or resolution of one or more of these contingencies. Whether any losses finally determined in any claim, action, investigation or proceeding or publicity related to such could reasonably have a material effect on the Company's business, financial condition, results of operations or cash flows will depend on a number of variables, in

Other Matters. In addition to the matters described above, the Company also may become involved in other litigation and regulatory matters incidental to its business and the matters disclosed in this quarterly report on Form 10-Q, including, but not limited to, product liability claims, regulatory actions, employment matters and commercial disputes. The Company intends to defend itself in any such matters and does not currently believe that the outcome of any such matters will have a material adverse effect on the Company's business, financial condition, results of operations and cash flows.

### Note 8 — Subsequent Events

On April 12, 2024, the Company entered into the 2024 Credit Facility.

In the event the Company borrows under the Line of Credit, interest will be payable commencing May 31, 2024, and then on the last day of each month thereafter until payment in full of all principal outstanding under the Line of Credit, with all

unpaid principal and interest due on April 12, 2027 (the "Expiration Date"). The Line of Credit will bear interest at a rate per year equal to the sum of (i) the greater of the Term SOFR Daily Floating Rate (as defined in the Loan Agreement) or 0.00%, plus (ii) 2.00%. Amounts under the Line of Credit may be repaid and re-borrowed from time to time until the Expiration Date.

The Company's obligations under the Loan Agreement are secured by a security interest in substantially all of the assets of the Company and the Guarantor, as further provided for in the Security and Pledge Agreement. Pursuant to the Continuing and Unconditional Guaranty, the Guarantor guarantees and promises to pay promptly to the Lender all indebtedness of the Company when due.

The Loan Agreement contains customary covenants, including affirmative and negative covenants that in certain circumstances restrict the Company's ability to incur additional indebtedness, make certain investments, purchase or otherwise acquire all or substantially all the assets or equity interests of other companies, or transfer any part of the business or any assets of the Company or the Guarantor. The Loan Agreement requires that the Company maintain specified financial ratios and satisfy certain financial condition tests.

The Loan Agreement contains certain customary events of default, including, among other things, failure of the Company to make required payments under the Loan Agreement, certain breaches of representations made by the Company or the Guarantor, insolvency or bankruptcy of the Company or the Guarantor, failure to have an enforceable first lien or security interest in any property given as security for the Loan Agreement, or failure of the Company to comply with covenants set forth in the Loan Agreement. If an event of default occurs under the Loan Agreement, the obligation of the Lender to make any additional credit available to the Company may be terminated and the amounts outstanding may become immediately due and payable in the discretion of the Lender, provided that in the event of insolvency or bankruptcy of the Company or the Guarantor, all debts outstanding under the Loan Agreement will automatically become due and payable. Upon the occurrence of any default or after maturity, all amounts outstanding under the Loan Agreement will at the option of the Lender bear interest at a rate which is 2.00% higher than the rate of interest otherwise provided under the Loan Agreement.

As of the date of this report, the Company has not borrowed under the 2024 Credit Facility.

# Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

### Overview

LifeVantage Corporation (the "Company,", "we," "us," or "our") is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. We are dedicated to helping people achieve their health, wellness and financial goals. We provide quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to our independent consultants. We engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath & body, and targeted relief products. We currently sell our products to customers and independent consultants in two geographic regions that we have classified as the Americas region and the Asia/Pacific & Furone region

The success and growth of our business is primarily based on the effectiveness of our independent consultants to attract and retain customers in order to sell our products and our ability to attract and retain independent consultants. When we are successful in attracting and retaining independent consultants and customers, it is largely because of:

- Our products, including our flagship Protandim® family of scientifically validated dietary supplements, LifeVantage® Omega+, ProBio, IC Bright®, Daily Wellness, Rise AM, Reset PM, and D3+ dietary supplements, our line of Nrf2 enhanced TrueScience® skin, hair, bath & body, and targeted relief products, Petandim®, our companion pet supplement formulated to combat oxidative stress in dogs, Axio®, our nootropic energy drink mixes, and PhysIQ™, our smart weight management system;
- · Our sales compensation plan and other sales initiatives and incentives; and
- Our delivery of superior customer service

As a result, it is vital to our success that we leverage our product development resources to develop and introduce compelling and innovative products and provide opportunities for our independent consultants to sell these products in a variety of markets. We sell our products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. We sold our products in China through a China approved cross-border e-commerce business model until March 15, 2023, at which time we closed our e-commerce business in China. In addition, we sell our products in a number of countries for personal consumption only. Entering a new market requires a considerable amount of time, resources and continued support. If we are unable to properly support an existing or new market, our revenue growth may be negatively impacted.

### COVID-19 Influence on Business Operations and Work Environment

We maintain both virtual and in person business operations in hybrid form, which started in 2020 as a result of the COVID-19 pandemic. We have continued to provide successful virtual events and trainings for our independent consultants and have been successful in conducting day to day business operations both in person, and over virtual platforms. During the COVID-19 pandemic, we implemented and continue to operate, a hybrid model with our employees working from home a few days a week and in the office a few days a week. We believe that this has worked well for employee productivity. We remain focused on being digital first and committed to increasing our investments in digital technologies and tools for independent consultants and employees to function effectively in the current hybrid working environment.

### Our Products

Our products are the Protandim® line of scientifically-validated dietary supplements, LifeVantage® Omega+, ProBio, IC Bright®, Rise AM, Reset PM, D3+ and Daily Wellness dietary supplements, TrueScience®, our line of skin, bath & body, targeted relief, and hair care products, Petandim®, our companion pet supplement formulated to combat oxidative stress in dogs, AXIO®, our nootropic energy drink mixes, and PhysIQ™ our smart weight management system. The Protandim® product line includes Protandim® NRF1 Synergizer®, and Protandim® NAD Synergizer®. The Protandim® NRF1 Synergizer® is formulated to increase cellular energy and performance by boosting mitochondria production to improve cellular repair and slow cellular aging. The Protandim® NrI2 Synergizer® contains a proprietary blend of ingredients and has been shown to combat oxidative stress and enhance energy production by increasing the body's natural antioxidant protection at the genetic level, inducing the production of naturally-occurring protective antioxidant enzymes, including superoxide dismutase, catalase, and glutathione synthase. The Protandim® NAD Synergizer® was specifically formulated to target cell signaling pathways involved in the synthesis and recycling of a specific molecule called NAD (nicotnamide adenine dinucleotide), and it has been shown to double sirtuin activity, supporting increased health, focus, energy, mental clarity and mood. Use of the three Protandim® products together, marketed as the Protandim® Tri-Synergizer®, has been shown to produce synergistic benefits greater than using the single products on their own. LifeVantage® Omega+ is a dietary supplement that combines DHA and EPA Omega-3 fatty acids, omega-7 fatty acids, and vitamin D3 to support designed to support immune health, skin health, and the immune system. LifeVantage® ProBio is a dietary supplement designed to support immune health. IC Bright® is a dietary supplement to help support eye and brain health, reduce eye fatigue and strain, support cognitive functions and may

We sell our products both individually and in stacks. A stack consists of multiple products bundled together that are designed to achieve a specific result. The Vitality Stack includes four of our nutrigenomics products — Protandim® NRF1 Synergizer®, Protandim® Nrf2 Synergizer®, LifeVantage® Omega+ and LifeVantage® ProBio. This product stack was designed to provide a foundation for wellness, supporting healthy organs, including the brain, heart, eyes, and other vitals. With the Ultimate Stack, we added Protandim® NAD Synergizer® and PhyslQ™ Prebiotic to our Vitality Stack to support gut health and increase sirtuin activity, supporting increased health, focus, energy, mental clarity and mood. The Protandim® Tri-Synergizer® consists of our Protandim® NRF1 Synergizer®, Protandim® NT2 Synergizer® and Protandim® NAD Synergizer®, and was designed to effectively and synergistically reduce oxidative stress, support mitochondria function, increase sirtuin activity, and target cell signaling pathways to fight the effects of aging. We also offer stacks that directly support the following consumer needs: immune support, heart health, energy, well-being, eye health, cognition and memory, metabolism, gut health, skin care, and hair care.

We currently have additional products in development. Any delays or difficulties in introducing compelling products or attractive initiatives or tools into our markets may have a negative impact on our revenue and our ability to attract new independent consultants and customers.

Compensation Plan for our Independent Consultants

On March 1, 2023, we launched a new compensation plan for our Independent Consultants in the United States, Japan, Australia, and New Zealand markets. We refer to this compensation plan as our Evolve Compensation Plan. On February 1, 2024, we launched the Evolve Compensation Plan in the Canada, Mexico, and Europe markets.

### Accounts

Because we primarily utilize a direct selling model for the distribution of a majority of our products, the success and growth of our business depends in large part on the effectiveness of our independent consultants to attract and retain customers to purchase our products and our ability to attract new and retain existing independent consultants. Changes in our product sales typically are the result of variations in product sales volume relating to fluctuations in the number of active independent consultants and customers purchasing our products. The number of active independent consultants and customers as a key non-financial measure.

The following tables summarize the changes in our active accounts base by geographic region. These numbers have been rounded to the nearest thousand as of the dates indicated. For purposes of this report, we define "Active Accounts" as only those independent consultants and customers who have purchased from us at any time during the most recent the control of the control of the purposes of this report, we define "Active Accounts" as only those independent consultants and customers who have purchased from us at any time during the most recent the control of the purposes of this report, we define "Active Accounts" as only those independent consultants and customers who have purchased from us at any time during the most recent the control of the purposes of this report, we define "Active Accounts" as only those independent consultants and customers who have purchased from us at any time during the most recent the control of the purposes of this report, we define "Active Accounts" as only those independent consultants and customers who have purchased from us at any time during the most recent the control of the purposes of this report, we define "Active Accounts" as only those independent consultants and customers who have purchased from us at any time during the most recent the control of the purposes of the purposes of the control of the purposes of the

		As of March 31,						
	2024		2023		Change from Prior Year	Percent Change		
Active Independent Consultants								
Americas	31,000	63.3 %	36,000	62.1 %	(5,000)	(13.9)%		
Asia/Pacific & Europe	18,000	36.7 %	22,000	37.9 %	(4,000)	(18.2)%		
Total Active Independent Consultants	49,000	100.0 %	58,000	100.0 %	(9,000)	(15.5)%		
Active Customers								
Americas	62,000	79.5 %	72,000	79.1 %	(10,000)	(13.9)%		
Asia/Pacific & Europe	16,000	20.5 %	19,000	20.9 %	(3,000)	(15.8)%		
Total Active Customers	78,000	100.0 %	91,000	100.0 %	(13,000)	(14.3)%		
Active Accounts								
Americas	93,000	73.2 %	108,000	72.5 %	(15,000)	(13.9)%		
Asia/Pacific & Europe	34,000	26.8 %	41,000	27.5 %	(7,000)	(17.1)%		
Total Active Accounts	127,000	100.0 %	149,000	100.0 %	(22,000)	(14.8)%		

# Results of Operations

### Three and Nine Months Ended March 31, 2024 and 2023

Revenue. We generated net revenue of \$48.2 million and \$53.7 million during the three months ended March 31, 2024 and 2023, respectively. We generated net revenue of \$151.2 million and \$159.2 million during the nine months ended March 31, 2024 and 2023, respectively. Foreign currency fluctuations negatively impacted our revenue \$0.8 million, or 1.5% and \$1.3 million, or 0.8%, during the three and nine months ended March 31, 2024, respectively.

Americas. The following table sets forth revenue for the three and nine months ended March 31, 2024 and 2023 for the Americas region (in thousands):

	Three Months Ended March 31,				Nine Months Ended March 31,				
	2024		2023	% Change		2024		2023	% Change
United States	\$ 35,333	\$	37,855	(6.7)%	\$	109,448	\$	110,485	(0.9)%
Other	1,882		1,677	12.2 %		5,347		5,121	4.4 %
Americas Total	\$ 37,215	\$	39,532	(5.9)%	\$	114,795	\$	115,606	(0.7)%

Revenue in the Americas region for the three and nine months ended March 31, 2024 decreased \$2.3 million, or 5.9%, and \$0.8 million, or 0.7%, respectively, from the prior year periods. Total Active Accounts decreased 13.9% in the region compared

to the prior year period. The average revenue per account increased due to changes in our product sales mix, driven primarily by our new TrueScience® Liquid Collagen product. Total TrueScience® Liquid Collagen related revenue, including the product when sold as part of a bundle, was approximately \$9.3 million and \$29.7 million for the three and nine months ended March 31, 2024, respectively, compared to approximately \$9.9 million and \$26.3 million in the prior year periods, respectively.

Asia/Pacific & Europe. The following table sets forth revenue for the three and nine months ended March 31, 2024 and 2023 for the Asia/Pacific & Europe region and its principal markets (in thousands):

	Thre	Three Months Ended March 31,			Nine Months E		
	2024		2023	% Change	2024	2023	% Change
Japan	\$	6,223	\$ 8,133	(23.5)%	\$ 21,051	\$ 23,665	(11.0)%
Australia & New Zealand		1,789	2,179	(17.9)%	6,200	6,295	(1.5)%
Greater China		966	811	19.1 %	2,163	2,810	(23.0)%
Other		2,052	3,086	(33.5)%	7,024	10,801	(35.0)%
Asia/Pacific & Europe Total	\$	11,030	\$ 14,209	(22.4)%	\$ 36,438	\$ 43,571	(16.4)%

Revenue in the Asia/Pacific & Europe region decreased \$3.2 million, or 22.4% and \$7.1 million, or 16.4%, for the three and nine months ended March 31, 2024, respectively, as compared to the prior year periods. Total Active Accounts in the region decreased 17.1% compared to the prior year period. Decreases in total Active Accounts, the closure of our e-commerce business in China, along with negative impacts from foreign currency exchange rate fluctuations, have contributed to the overall decrease in revenue within the Asia/Pacific & Europe region.

Overall, revenue in the Asia/Pacific & Europe region was negatively impacted by foreign currency exchange rate fluctuations in the amount of approximately \$0.9 million, or 6.3% and \$1.5 million, or 3.5%, during the three and nine months ended March 31, 2024, respectively, as compared to the prior year periods, mainly due to currency fluctuations in the amount of approximately \$0.8 million, or 9.3% and \$1.4 million, or 6.0%, during the three and nine months ended March 31, 2024, respectively, as compared to the prior year periods. On a constant currency basis, revenue in Japan during nine months ended March 31, 2024, respectively, as compared to the prior year periods. The decrease in revenue on a constant currency basis in Japan during nine months ended March 31, 2024 was due to our Active Accounts in that region increasing their purchases in September 2022, ahead of price increases that went into effect on October 1, 2022. The decrease was offset by increases in the average revenue per account, primarily from TrueScience\* Liquid Collagen related revenue which started selling in Japan in March 2023. Revenue related to TrueScience\* Liquid Collagen was approximately \$0.8 million and \$3.7 million for the three and nine months ended March 31, 2024, respectively.

Globally, our sales and marketing efforts continue to be directed toward strengthening our core business through our fiscal year initiatives and building our worldwide revenue. In March 2024, we launched our TrueScience\*
TrueClean Refining Cleanser, TrueLift Illuminating Eye Cream, and TrueHydrate Brightening Moisturizer, which, together with the launch of TrueRenew Daily Firming Complex in October 2023, resulted in the completion of the launch of our new TrueScience\* Activated Skin Care Collection. We also launched TrueScience\* TrueProtect Daily Mineral Sunstick. During fiscal year 2024, we launched our TrueScience\* Liquid Collagen in our Philippines, Canada, Mexico, and Europe markets. Revenue related to these products has offset decreases in our Active Accounts in these regions by increasing our overall average revenue per account. We have seen and continue to expect that these product launches will help drive revenue growth globally through increased average order size and increased ability to attract and retain new independent consultants and customers with a compelling product lineup.

Cost of Sales. Cost of sales were \$10.2 million and \$10.6 million for the three months ended March 31, 2024 and 2023, respectively, resulting in gross profit percentages of 78.9% and 80.2%, respectively. Cost of sales were \$31.4 million and \$32.3 million for the nine months ended March 31, 2024 and 2023, respectively, resulting in gross profit percentages of 79.2% and 79.7%, respectively. The increase in cost of sales as a percentage of revenue is primarily due to a shift in product mix, changes in raw material and manufacturing related costs, shipping to customer expenses, and warehouse fulfillment expenses during three and nine months ended March 31, 2024.

Commissions and Incentives. Commissions and incentives expenses during the three months ended March 31, 2024 were \$19.7 million or 40.9% of revenue as compared to \$23.8 million or 44.3% of revenue for the three months ended March 31, 2023. Commissions and incentives expenses during the nine months ended March 31, 2024 were \$63.9 million or 42.3% of revenue as compared to \$71.2 million or 44.7% of revenue for the nine months ended March 31, 2023. The decrease in commissions and incentives expenses as a percentage of revenue compared to the prior year periods is due to changes in sales mix, timing and magnitude of our various promotional and incentive programs, and decreases in commission expenses as a

result of the change to our Evolve Compensation Plan in March 2023 in the United States, Australia, New Zealand, and Japan markets, as well as in Canada, Mexico, and Europe markets in February 2024.

Commissions and incentives expenses, as a percentage of revenue, may fluctuate in future periods based on ability to hold incentive trips and events and the timing and magnitude of compensation, incentive and promotional programs.

Selling, General and Administrative. Selling, general and administrative expenses during the three months ended March 31, 2024 were \$16.4 million or 34.0% of revenue as compared to \$17.7 million or 33.0% of revenue for the three months ended March 31, 2023. Selling, general and administrative expenses during the nine months ended March 31, 2024 were \$54.5 million or 36.0% of revenue as compared to \$54.0 million or 33.9% of revenue for the nine months ended March 31, 2023. The increase in selling, general and administrative expenses as a percentage of revenue during the three and nine months ended March 31, 2024 compared to the prior year periods is primarily due to increased proxy contest related expenses. These increases have been partially offset by decreases in event costs, endorsement agreements, employee compensation related expenses, office lease and professional services expenses.

Total Other Income (Expense). During the three months ended March 31, 2024 we recognized total net other expense of \$13,000 as compared to income of \$0.1 million for the three months ended March 31, 2023. During the nine months ended March 31, 2024 we recognized total net other income of \$0.2 million for the nine months ended March 31, 2023. Total net other income (expense) for the three and nine months ended March 31, 2024 and 2023 consisted primarily of interest income, offset by foreign currency gains and losses.

Income Tax Expense. We recognized income tax expense of \$0.6 million and \$7,000 for the three and nine months ended March 31, 2024, respectively, as compared to income tax expense of \$0.6 million and \$0.9 million for the three and nine months ended March 31, 2023, respectively.

The change in the effective tax rate for the nine months ended March 31, 2024 compared to the prior year period was primarily due to changes in taxable income and the impact of discrete items.

We expect that our effective tax rate will fluctuate slightly during the remainder of fiscal 2024 as the impact of discrete items and other permanent differences are recognized during the year; however, our tax rate can be impacted by various book to tax differences and fluctuations in our stock price that occur during the year which are difficult to forecast.

## **Liquidity and Capital Resources**

### Liquidity

Our primary liquidity and capital resource requirements are to finance the cost of our planned operating expenses and working capital (principally inventory purchases), fund capital expenditures, and service our debt, which includes any outstanding balances under a credit facility. We have generally relied on cash flow from operations to fund operating activities and we have, at times, incurred long-term debt in order to fund stock repurchases and strategic transactions.

As of March 31, 2024, our available liquidity was \$17.4 million, which consisted of available cash and cash equivalents. This represents a decrease of \$4.2 million from the \$21.6 million in cash and cash equivalents as of June 30, 2023

During the nine months ended March 31, 2024, our net cash provided by operating activities was \$9.6 million as compared to \$3.1 million during the nine months ended March 31, 2023.

During the nine months ended March 31, 2024, our net cash used in investing activities was \$2.0 million, as a result of the purchase of fixed assets. During the nine months ended March 31, 2023, our net cash used in investing activities was \$2.6 million, as a result of the purchase of fixed assets.

Cash used in financing activities during the nine months ended March 31, 2024 was \$11.7 million as a result of our payment of cash dividends, repurchases of common stock, and shares purchased as payment of tax withholding upon vesting of equity awards, partially offset by proceeds from stock issued under our employee stock purchase plan. Cash used in financing activities during the nine months ended March 31, 2023 was \$1.0 million as a result of our repurchase of common stock, and shares purchased as payment of tax withholding upon vesting of equity awards, partially offset by proceeds from stock issued under our employee stock purchase plan and stock option exercises.

At March 31, 2024 and June 30, 2023, the total amount of our foreign subsidiary cash was \$7.6 million and \$6.2 million, respectively. The federal tax reform legislation that was passed into law during December 2017 enacted a 100% dividend deduction for greater than 10% owned foreign corporations. Therefore, in the future, if needed, we expect to be able to repatriate cash from foreign subsidiaries without paying additional U.S. taxes.

At March 31, 2024, we had working capital (current assets minus current liabilities) of \$15.3 million, compared to working capital of \$24.7 million at June 30, 2023. We believe that our cash and cash equivalents balances and our ongoing cash flow from operations will be sufficient to satisfy our cash requirements for at least the next 12 months. The majority of our historical expenses have been variable in nature and as such, a potential reduction in the level of revenue would reduce our cash flow needs. In the event that our current cash balances and future cash flow from operations are not sufficient to meet our obligations or strategic needs, we would consider raising additional funds, which may not be available on terms that are acceptable to us, or at all. Our 2024 Credit Facility (as defined below), provides for a revolving line of credit in an aggregate principal amount not to exceed \$5.0 million. We would also consider realigning our strategic plans including a reduction in capital spending and expenses.

### Capital Resources

Shelf Registration Statement

On March 31, 2023, we filed a shelf registration statement on Form S-3 (the "2023 Shelf Registration") with the SEC that was declared effective on April 6, 2023, which permits us to offer up to \$75 million of common stock, preferred stock, debt securities and warrants in one or more offerings and in any combination, including in units from time to time. Our 2023 Shelf Registration is intended to provide us with additional flexibility to access capital markets for general corporate purposes, which may include, among other purposes, working capital, capital expenditures, other corporate expenses and acquisitions of assets, licenses, products, technologies or businesses.

### Credit Facility

On March 30, 2016, we entered into a loan agreement (the "2016 Loan Agreement") and a security agreement (the "Security Agreement"). The 2016 Loan Agreement provides for a term loan in an aggregate principal amount of \$10.0 million (the "2016 Term Loan") and a revolving loan facility in an aggregate principal amount not to exceed \$2.0 million (the "2016 Revolving Loan," and collectively with the 2016 Term Loan, the 2016 Loan Agreement and the Security Agreement, the "2016 Credit Facility" and together with the amendments described below, the "Credit Facility"). During the fiscal year ended June 30, 2020, we repaid, in full, the balance of the 2016 Term Loan.

On May 4, 2018 and February 1, 2019, we entered into loan modification agreements ("Amendment No. 1" and "Amendment No. 2", respectively). These loan modification agreements amended certain financial covenants and the available borrowing amount under the 2016 Revolving Loan.

On April 1, 2021, we entered into a loan modification agreement ("Amendment No. 3"), which further amended the Credit Facility, as previously amended, to provide for an available borrowing amount of \$5.0 million, a revised maturity date from March 31, 2021 to March 31, 2024, and a modified variable interest rate based on the one-month United States Treasury Rate, plus a margin of 3.00%, with an interest rate floor of 4.00%. Amendment No. 3 also revised the debt (total liabilities) to tangible net worth ratio (as defined in Amendment No. 3) covenant to require that the company maintain this ratio not in excess of 2.00 to 1.00, measured as of the end of each fiscal quarter, and revised the definition and calculation of the minimum fixed charge coverage ratio (as defined in Amendment No. 3). There were no other changes to the minimum fixed charge coverage ratio of 1.10 to 1.00 or the minimum working capital of \$6.0 million as set forth in previous amendments.

We entered into a loan modification agreement ("Amendment No. 4"), effective September 30, 2022, which further amended the Credit Facility. Amendment No. 4 revised the calculation of the minimum fixed charge coverage ratio (as defined in Amendment No. 4) and allowed us to declare and pay dividends, up to \$500,000 per quarter, through September 30, 2023. There were no other changes to the covenants or revolving loan facility as set forth in

On August 28, 2023, we received approval, without modifying Amendment No. 4, to declare and pay a one-time cash dividend of \$0.40 per share of common stock, to be paid on September 22, 2023. We also received approval to declare and pay dividends, up to \$750,000 per quarter, through September 30, 2024.

On March 31, 2024, the Credit Facility reached the maturity date and no further loan modifications were entered into. As of March 31, 2024, there was no balance outstanding on this Credit Facility.

### 2024 Credit Facility

On April 12, 2024, we entered into a Loan Agreement (the "Loan Agreement") with Bank of America, N.A., as Lender (the "Lender"). In connection with the Loan Agreement and on the same date, we, Lifeline Nutraceuticals Corporation, as Guarantor (the "Guarantor"), and the Lender also entered into a Continuing and Unconditional Guaranty (the "Continuing and Unconditional Guaranty") and a Security and Pledge Agreement (the "Security and Pledge Agreement"). The Loan Agreement provides for a revolving line of credit in an aggregate principal amount not to exceed \$5.0 million (the "Line of Credit") and

collectively with the Loan Agreement, the Continuing and Unconditional Guaranty and the Security and Pledge Agreement, the "2024 Credit Facility."

In the event we borrow under the Line of Credit, interest will be payable commencing May 31, 2024, and then on the last day of each month thereafter until payment in full of all principal outstanding under the Line of Credit, with all unpaid principal and interest due on April 12, 2027 (the "Expiration Date"). The Line of Credit will bear interest at a rate per year equal to the sum of (i) the greater of the Term SOFR Daily Floating Rate (as defined in the Loan Agreement) or 0.00%, plus (ii) 2.00%. Amounts under the Line of Credit may be repaid and re-borrowed from time to time until the Expiration Date.

Our obligations under the Loan Agreement are secured by a security interest in substantially all of the assets of the Company and the Guarantor, as further provided for in the Security and Pledge Agreement. Pursuant to the Continuing and Unconditional Guaranty, the Guarantor guarantees and promises to pay promptly to the Lender all indebtedness of the Company when due.

The Loan Agreement contains customary covenants, including affirmative and negative covenants that in certain circumstances restrict our ability to incur additional indebtedness, make certain investments, purchase or otherwise acquire all or substantially all the assets or equity interests of other companies, or transfer any part of the business or any assets of the Company or the Guarantor. The Loan Agreement requires us to maintain specified financial ratios and satisfy certain financial condition tests.

The Loan Agreement contains certain customary events of default, including, among other things, our failure to make required payments under the Loan Agreement, certain breaches of representations made by us or the Guarantor, insolvency or bankruptcy of the Company or the Guarantor, failure to have an enforceable first lien or security interest in any property given as security for the Loan Agreement, or our failure to comply with covenants set forth in the Loan Agreement. If an event of default occurs under the Loan Agreement, the obligation of the Lender to make any additional credit available to us may be terminated and the amounts outstanding may become immediately due and payable in the discretion of the Lender, provided that in the event of insolvency or bankruptcy of the Company or the Guarantor, all debts outstanding under the Loan Agreement will automatically become due and payable. Upon the occurrence of any default or after maturity, all amounts outstanding under the Loan Agreement will at the option of the Lender bear interest at a rate which is 2.00% higher than the rate of interest otherwise provided under the Loan Agreement.

As of the date of this report, we have not borrowed under the 2024 Credit Facility.

### Commitments and Obligations

Please refer to Note 7 to the condensed consolidated financial statements contained in this report for information regarding our contingent liabilities.

### Critical Accounting Policies and Estimates

We prepare our financial statements in conformity with accounting principles generally accepted in the United States of America. As such, we are required to make certain estimates, judgments, and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the periods presented. Actual results could differ from these estimates. Our significant accounting policies are described in Note 2 to our consolidated financial statements. Certain of these significant accounting policies require us to make difficult, subjective, or complex judgments or estimates. We consider an accounting estimate to be critical if (1) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made and (2) changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations.

There are other items within our financial statements that require estimation but are not deemed critical as defined above. Changes in estimates used in these and other items could have a material impact on our financial statements. Management has discussed the development and selection of these critical accounting estimates with our Board of Directors, and our audit committee has reviewed the disclosures noted below.

### Inventory Valuation

We value our inventory at the lower of cost or net realizable value on a first-in first-out basis. Accordingly, we reduce our inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability equal to the difference between the cost of the inventory and its net realizable value. Factors utilized in the determination of net realizable value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive

pricing pressures, (iv) new production introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

During the three and nine months ended March 31, 2024 we recognized expenses of approximately \$0.4 million and \$0.7 million, respectively, related to obsolete and slow-moving inventory. During the three and nine months ended March 31, 2023 we recognized expenses of approximately \$0.3 million and \$0.7 million, respectively, related to obsolete and slow-moving inventory.

### Stock-Based Compensation

We use the fair value approach to account for stock-based compensation in accordance with current accounting guidance. We recognize compensation costs for awards with performance conditions when we conclude it is probable that the performance conditions will be achieved. We reassess the probability of vesting at each balance sheet date and adjust compensation costs based on our probability assessment. For awards with market-based performance conditions, the cost of the awards is recognized as the requisite service is rendered by the employees, regardless of when, if ever, the market-based performance conditions are satisfied.

Historically, our estimates and underlying assumptions have not materially deviated from our actual reported results and rates. However, we base the assumptions we use on our best estimates, which involves inherent uncertainties based on market conditions that are outside of our control. If actual results are not consistent with the assumptions we use, the stock-based compensation expense reported in our consolidated financial statements may not be representative of the actual economic cost of stock-based compensation. For example, if actual employee forfeitures significantly differ from our estimated forfeitures, we may be required to adjust our consolidated financial statements in future periods.

### Income Taxes

The provision for income taxes includes income from U.S. and foreign subsidiaries taxed at statutory rates, the accrual or release of amounts for tax uncertainties, and U.S. tax impacts of foreign income in the U.S.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the carrying amounts of assets and liabilities on the financial statements and their respective tax bases. Deferred tax assets also are recognized for net operating losses and credit carryforwards. Deferred tax assets and liabilities are measured using the enacted rates applicable to taxable income in the years in which the temporary differences are expected to reverse and the credits are expected to be used. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. An assessment is made as to whether or not a valuation allowance is required to offset deferred tax assets. This assessment requires estimates are made on an ongoing basis based upon our business plans and growth strategies in each market and consequently, future material changes in the valuation allowance are possible. The valuation allowance reduces the deferred tax assets to an amount that management determined is more-likely-than-not to be realized.

We operate in and file income tax returns in the U.S. and numerous foreign jurisdictions with complex tax laws and regulations, which are subject to examination by tax authorities. The complexity of our global structure requires specialized knowledge and judgment in determining the application of tax laws in various jurisdictions. Years open to examination contain matters that could be subject to differing interpretations of applicable tax laws and regulations related to the amount and/or timing of income, deductions, and tax credits. We account for uncertain tax positions in accordance with Accounting Standards Codification ("ASC") 740, Income Taxes. This guidance prescribes a minimum probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is defined as a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement.

Interest and penalties related to tax contingency or settlement items are recorded as a component of the provision for income taxes in our Consolidated Statements of Operations and Comprehensive Income. We record accruals for tax contingencies as a component of accrued liabilities or other long-term liabilities on our Consolidated Balance Sheet.

# Item 3. Quantitative and Qualitative Disclosures About Market Risk

This item is not required for smaller reporting companies

### Item 4. Controls and Procedures

### Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act of 1934, as amended) that are designed to ensure that the information required to be disclosed in the reports we file or submit under the Exchange Act of 1934, as amended, is (a) recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and (b) accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. As of the end of the period covered by this quarterly report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness and design and operation of such disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were designed and operating effectively as of March 31, 2024.

### Changes in Internal Control over Financial Reporting

An evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 of the Exchange Act of 1934, as amended, was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter. That evaluation did not identify any changes in our internal control over financial reporting during the three months ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Inherent Limitations of Internal Control Over Financial Reporting

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### PART II. Other Information

# Item 1. Legal Proceedings

See Note 7 to our unaudited condensed consolidated financial statements contained within this quarterly report on Form 10-Q for a discussion of our legal proceedings.

### Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in "Part I. Item 1A — Risk Factors" in our annual report on Form 10-K for the fiscal year ended June 30, 2023, filed on August 28, 2023. The risks and uncertainties described in such risk factors and elsewhere in this report have the potential to materially affect our business, financial condition, results of operations, cash flows, projected results and future prospects. We do not believe that there have been any material changes to the risk factors previously disclosed in our recent SEC filings, including our most recently filed Form 10-K, as referenced above, as updated by our Quarterly Report on Form 10-Q for the quarter ended December 31, 2023, filed on January 30, 2024.

## Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides information with respect to all purchases of our common stock made by or on behalf of the Company or any "affiliated purchaser," as defined in Rule 10b-18 under the Exchange Act, during the three months ended

March 31, 2024. All purchases listed below were made in the open market at prevailing market prices.

Period	Total Number of Shares Purchased	 Average Price Paid Per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs <sup>(1)</sup>	laximum Dollar Value of Shares that ay Yet Be Purchased Under the Plans or Programs <sup>(1)</sup>
January 1 - January 31	69,178	\$ 5.84	69,178	\$ 23,776,731
February 1 - February 29	125,763	\$ 6.72	125,763	\$ 22,931,443
March 1 - March 31	96,968	\$ 6.99	96,968	\$ 22,253,206
Total	291,909		291,909	

<sup>1.</sup> On November 27, 2017, our Board of Directors approved a stock repurchase program, as amended on February 1, 2019, August 27, 2020, February 17, 2022, and June 12, 2023. Under the program, we are authorized to repurchase up to \$60.0 million of our outstanding shares through December 31, 2026. The repurchase program permits us to purchase shares from time to time through a variety of methods, including in the open market, through privately negotiated transactions or other means as determined by our management, in accordance with applicable securities laws. As part of the repurchase program, we have authorized a pre-arranged stock repurchase plan which operates in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Accordingly, any transactions under such stock repurchase plan will be completed in accordance with the terms of the plan, including specified price, volume and timing conditions. The authorization may be suspended or discontinued at any time.

# Item 3. Defaults Upon Senior Securities

Mono

## Item 4. Mine Safety Disclosures

Not applicable.

# Item 5. Other Information

During the three months ended March 31, 2024, none of the Company's directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) informed the Company of adoption, modification or termination of a "Rule 10b5-1 trading arrangement," or non-Rule 10b5-1 trading arrangement," as defined in Item 408 of Regulation S-K.

Item 6. Exhibits Exhibit No.	Document Description	Filed Herewith or Incorporate by Reference From
Exhibit No.	Document Description	Fact referring of incorporate by Reference From
3.1	Certificate of Incorporation, as filed with the Delaware Secretary of State on March 9, 2018	Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on March 13, 2018.
3.2	Amended and Restated Bylaws, August 9, 2019	Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on August 15, 2019.
3.3	Certificate of Designation of Series A Junior Participating Preferred Stock of Registrant	Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on August 31, 2023.
4.1	Rights Agreement, dated as of August 30, 2023, between the Registrant and Computershare Trust Company, N.A., as Rights Agent	Exhibit 4.1 to the Current Report on Form 8-K filed with the SEC on August 31, 2023.
10.1	Cooperation Agreement, by and among the Company, the entities and person listed on Exhibit A thereto, and the entities and person listed on Exhibit B thereto, dated February 14, 2023	Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on February 15, 2024.
10.2	Loan Agreement, dated as of April 12, 2024, between LifeVantage Corporation and Bank of America	Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on April 16, 2024

10.3	Continuing and Unconditional Guaranty, dated as of April 12, 2024, among LifeVantage Corporation, as Borrower, Lifeline Nutraceuticals Corporation, as Guarantor, and Bank of America, N.A.	Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on April 16, 2024.
10.4	Security and Pledge Agreement, dated as of April 12, 2024, among LifeVantage Corporation, as Borrower, Lifeline Nutraceuticals Corporation, as Guarantor, and Bank of America, N.A.	Exhibit 10.3 to the Current Report on Form 8-K filed with the SEC on April 16, 2024.
10.5	Evolve Compensation Plan (Canada)	Filed herewith.
10.6	Evolve Compensation Plan (Mexico)	Filed herewith.
10.7	Evolve Compensation Plan (UK)	Filed herewith.
10.8	Evolve Compensation Plan (EU)	Filed herewith.
31.1	Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a)	Filed herewith.
31.2	Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a)	Filed herewith.
32.1*	Certification of principal executive officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith.
32.2*	Certification of principal financial officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith.
101	The following financial information from the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2024 aformatted in Inline XBRL (extensible Business Reporting Language): (i) Unaudited Condensed Consolidated Balance Sheets at March 31, 2024 and June 30, 2023; (ii) Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Income for the three and nine months ended March 31, 2024 and 2023; (iii) Unaudited Condensed Consolidated Statement of Stockholders' Equity for the three and nine months ended March 31, 2024 and 2023; (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended March 31, 2024 and 2023; and (v) Notes to Unaudited Condensed Consolidated Financial Statements, tagged as blocks of text.	Filed herewith.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101	Filed herewith

<sup>\*</sup> This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and is not being filed for purposes of Section 18 of the Exchange Act and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing

# SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

LIFEVANTAGE CORPORATION

May 2, 2024

Date:

Date:

May 2, 2024

/s/ Steven R. Fife Steven R. Fife President and Chief Executive Officer (Principal Executive Officer)

/s/ Carl A. Aure
Carl A. Aure
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)





POSE.
Life. 8's complicated Messy Beautiful It goes by fast, and you want to live life to the fullest. But sevelyer responsibles, Rears, or restrictions. Rears, or restrictions. Rears, or restrictions.

IT'S TIME TO LIVE WITH PURPOSE.
IT'S TIME TO INSPIRE REMARKABLE.
IT'S TIME TO LIVE ACTIVATED.

KEY TERMS	
THE CONSULTANT PATH	6.7
SHARE	
FAST TRACK BONUSES	
BUILD & GROW	
LEAD	
LEGAL MOTICE	-

# Key Terms



# The Consultant Path

SHARE Preçois say our products are too great not to shared in the early stapes of your business, begin with a strong compliance, begin with a strong compliance on stable products our reference products by selling our welfmest products by selling our welfmest products by selling our sellines state sales are the factor of the selling and sponsoring, which is vital to your continued growth. The larger you grown your states sales are the factor of the selling and sponsoring, which is vital to your continued growth. The larger you grown your sales same, the more time you will speece building your business and see a speecty profit.

	a CONSULTANT		E CONSULTANT 2	2 CONSULTANT 3	SENIOR CONSULTANT 1	SEMICH CONSULTANT 2		E MANAGING E CONSULTANT 1	MANAGING CONSULTANT 2	MANAGING CONSULTANT 3		EXECUTIVE CONSULTANT 2	
PERSONAL SALES VOLUME CAP	150	150	150	150	150	150	150	150	150	150	150	150	150
SALES VOLUME REQUIREMENT		150	200	250	300	300	300	300	300	300	300	300	300
GROUP SALES VOLUME			500	1,000	2,000	3,500	6,000	10,000	20,000	40,000	80,000	150,000	300,000
MAXIMUM VOLUME RULE				750	1,500	2,500	4,000	6.000	10,000	20,000	40,000	67,500	135,000

CAL	
Share. Build & Gro Lead.	W.
You point as an independent LifeVariage Consultant can load to a world of possibilities. Start by sharing the LifeVariage products that you love with Customers to help them activate wellness and improve their health. The more you share, the more you! grow as you find others who want to join you an the path with a business of their own.  As you progress along the Consultant Path, your attention will shift to building and leading Consultants on your team who are ready to grow to the next stage of success. At every stage you'll evolve your earnings, yourself, and your life.	HOW IT WORKS: You must meet certain volume requirements to stay Active and earn boriuses and commissions.  These requirements will change, along with the bonuses and commissions you can qualify for a you move along the path and earn Rank advancements.  As you reach the qualifications for a specific Rank, you will be recognized with your "Pin Rank" at that level for as long as you remain Active, However, your "Palld as Rank" will fluctuate with your qualifications from month to month.



# Share.

Sharing your excitement about LifeVantage and selling products to Customers is at the heart of being a Consultant. In addition to Customer Sales Profit, you m on total monthly product sales with the Personal Sales Bonus.

# Customer Sales Profit

Customer Sales Profit allows you to earn commissions on every order. Here's how if works: When your Customers order LifeVirntage products, you earn the difference between the price your Customer paid and the Consultant price for which you qualify. Your price as a Consultant start is the Consultant start on Price, util you unlock the Consultant start of the Consultant starts of the Consultant starts on the Consultant starts on the Consultant start or the Consultant start of the Consultant Price by ochieving 500 CSV once every 6 months.

### IN PRACTICE

IN PRACTICE
In these examples, 2 Customers are ordering the same set of products. The Customer on the left purchases the products at the full One-time Retail price of "\$130.1 If you have not unlocked the Consultant Price, then your price for that order is the Consultant Base Price or "\$150.50.50, you exen a Customer Sales Prioff or "\$150.1 If you have unlocked the Consultant Price, then your price for that order is the Consultant Price or "\$150.4 So, you exen a Customer Sales Prioff or "\$250. The Customer on the right orders the same products on a Subscription and erfor for the Suscription Price of "\$711. If you have not unlocked the Consultant Price, then your price for that order is the Consultant Base Price or "\$150.50.50, you exen a Customer Sales of Prioff or "\$55.0 If you have unlocked the Consultant Price, then your price for that order is the Consultant Price or "\$150.4, So, you exen a Customer Sales of the Consultant Price or "\$150.4, So, you exen a Customer Sales of the Consultant Price or "\$150.4, So, you exen a Customer Sales Prioff of "\$13.

### CUSTOMER SALES PROPIT IS CALCULATED DAILY!





# Share.

# Personal Sales Bonus

The Personal Sales Bonus rewards you on your personal Customer sales. When your personal Customer sales total 500 SV or more in a single month, you become eligible for an additional Personal Sales Bonus. The bonus is paid on a percentage of CV.

When you reach 500 Customer Sales Volume in a single month, you will be recognized with a special title before your Rank, starting with Onyx at 500 SV then changing to Emerald at 1000 SV, Sepphire at 2000 SV, and Diamond at 4000 SV and higher.

IN PRACTICE
For example, if your Customers order 2200 SV worth of products in the month, you are elligible for the 15% bonus list. This bonus is paid on CV which takes into account promose or discounts Customers may have redeemed. For illustration purposes only, if the theoretical PEG Rate for Canada at the time this bonus is calculated were 13.0, then the bonus amount in local currency would be calculated as follows:

- SV is multiplied by the PEG Rate to get the CV. CV is then multiplied by the applicable bonus percentage.
- 2200 SV X 1.30 (theoretical Canada PEG Rate) X 15% = <sup>13</sup>\$429.



15% of CV

PERSONAL SALES BONUS and the little of

SAPPHIRE

PERSONAL SALES BONUS IS CALCULATED MONTHLY

CUSTOMER	BONUS TIER	RECOGN
500 - 999.99	53	OH
1,000 - 1,099.99	10%	EMES



# Consultant



## of Customer Track

## 02 Consultant Track

These bonuses can boost you right from the start. Your Fast Track Period begins the day you enroll as a Consultant and continues through the next 3 calendar months

## 93 RankAdvancement Track

## 04 Accelerator Track











When you advance to the Rank of SENIOR CONSULTANT 1





# Enroller

## 21 Rank Advancement Track

If you are Paid-as Senior Consultant 1 or higher, you can earn a one-time \*\*\$65 Enroller Bonus anytime your newly enrolled Consultant earns a Rank Advancement Bonus. Calculation based on \*\*\$50 X 1.30 (theoretical CA PER Burs) \*\*\*\$85.

ENROLLER EARNS 4565

## 02 Accelerator Track

If you are Active in the month a Consultant you entroll earns an Accelerator Track Bonus, you can earn a \*\*\$32,50 bonus as their Enroller. Calculation based on \*\*\$25 X 1.30 (theoretical CA PEG Ratio = \*\*\$32,50.



## ENROLLER EARNS \*\*\$32.50

Upline Enroller earns the Accelerator

ACCELERATOR TRACK

# Earn When You Help Others Win on The Fast Track

The first few months of a new Consultant's business are critical to setting them up for a future of success. As their Enroller, work closely with them during their Fast Track Period to help them get started right and you could also earn bonness.

## Mentor Bonus

To receive any Mentor Bonus, you must be Active in the month your new Consultant qualifies. Earn 15% of all your new Consultant's CV from their Customer sales during their Fast Track Period.



MENTOR BONUS IS CALCULATED MONTHLY

#### IN PRACTICE

IN PRACTICE In this example, if your newly enrolled Consultant during their Fast Track Period, you earn a 15% bor purposes only, if the theoretical PEG Rate for Can this borus is calculated were 1.30, then the bonus currency would be calculated as follows:

- SV is multiplied by the theoretical PEG Rate to
  CV is then multiplied by the applicable bonus
- 500 SV X 1.30 (theoretical CA PEG Rate) X 1

Mint he Artise to quality



## **Level Commissions**

All of the Consultants directly below you in your Placement Tree are your Level 1. Consultants are paid Customers Sales Profit and Personal Sales Bonus on their personally enrolled Customer purchases. Enrollers are not eligible for a Level Commission on their personal Customers. LEVEL COMMISSIONS ARE CALCULATED MONTHLY

	n CONSULTANT		2 CONSULTANT 2	2 CONSULTANT 3	SENIOR CONSULTANT 1			E MANAGING CONSULTANT	A MANAGING CONSULTANT 2	R MANAGING CONSULTANT 3					PRESIDENTIAL CONSULTANT
PSVC	150	150	150	150	150	150	150	150	150	150	150	150	150	150	150
SVR		150	200	250	300	300	300	300	300	300	300	300	300	300	300
GSV			500	1,000	2,000	3,500	6,000	10,000	20,000	40,000	80,000	150,000	300,000	600,000	1,000,000
MVR				750	1,500	2,500	4,000	6,000	10,000	20,000	40,000	67,500	135,000	270,000	410,000
LEVEL 1		5%	7%	9%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%
LEVEL 2				25	5%	6%	75	7%	7%	75	75	2%	7%	7%	7%
<b>TEAET 3</b>						2%	5%	6%	7%	7%	7%	7%	2%	7%	7%
LEVEL 4							2%	5%	6%	6%	6%	6%	6%	6%	6%
LEVEL 5								3%	SX	6%	6%	6%	6%	6%	6%
LEVEL 6									2%	4%	5%	55	5%	5%	5%
LEVEL 7									25	45	4%	4%	45	4%	4%
<b>LEVEL 8</b>										35	3%	3%	25	3%	35
LEVEL 9										3%	3%	3%	3%	3%	3%

## Active Compression PRESIDENTIAL O Active PC is qualified for Level 9 and paid 3%. INACTIVE Inactive. Through Active Compression, this Level is not qualified and Level 9 rolls up. IN PRACTICE This example shows how volume could roll up in one Leg of a team. You're a Senior Consultant 3 at Level 5 above the Consultant who earned the volume. Starting from the bottom of the chart, you see how CV flows up and what happens below and above you. EC3 New Level 6 is an Active EC3 qualified to earn on 9 Levels. They are paid Level 6 at 5%. INACTIVE Inactive. Through Active Compression, this Level is not qualified MC3 a Active MC3 qualified to earn on 9 Levels and paid on Level 5 at SC3 Because the Consultant below you is inactive, you become Le Compression. As an Active SC3, you are qualified to earn at Li INACTIVE Inactive. Through Active Compression, this Level is not qualified C3 Active C3 is qualified to earn on only 2 Levels. This is Level 3, so they are not eligible and Level 3 is not paid. C1 Active C1 qualified to earn on Level 1. This is Level 2, so they are not eligible and Level 2 is not paid. KEY

Qualified (Paid)

Inactive (Rolls Up)

Not Qualified (Not Paid)



## Leadership Match

When you are paid as a Managing Consultant 2 or higher in the month, you can receive a Leadership Match on qualified Generations. The Leadership Match is paid on your qualified Generations' Level Commissions.

#### HOW GENERATIONS WORK

Your Generation 1 is the first Consultant in any Leg in your team with a Paid-as Rank of Menaging Consultant 1 or higher. A Generation 2 is the next Consultant in that Leg with a Paid-as Rank of Managing Consultant 1 or higher, and so on.

GENERATION 2

GENERATION 5

GENERATION 7

CAP PER MATCH

For Illustration purposes only, if the theoretical PEG Rate for Canada at the time this bonus is calculated were 1.30, then the borus amount in local currency would be calculated as follows:

 Cap Per Match amount in US\$ is multiplied by the theoretical CA PEG Rate.

 For example, the Cap Per Match for a Managing Consultant 2 would be <sup>US</sup>\$1,000 X 1.30 (theoretical CA PEG Rate) = <sup>US</sup>\$1,300.

LEADERSHIP MATCH IS CALCULATED MONTHLY

MONTHLY LEADERSHIP MATCH CAN PAYOUT UP
TO A MAXIMUM OF BY OF MONTHLY GLOBAL CV.


18

When you reach the Leader level, you've shown you truly know what it takes to succeed and have the skills to help mentor and motivate others. Keep cultivating your future leaders and helping them grow and you can earn substantial bonuses for building such a strong team.

MANAGING CONSULTANT 2	MANAGING CONSULTANT 3	EXECUTIVE CONSULTANT 1	EXECUTIVE CONSULTANT 2		EXECUTIVE CONSULTANT 8	PRESIDENTIAL
75	12%	15%	20%	20%	20%	20%
	10%	125	15%	20%	20%	20%
		10%	12%	15%	20%	20%
			10%	12%	15%	20%
				10%	12%	15%
					10%	12%
						12%
\$1,000	\$2,500	\$5,000	\$7,500	\$10,000	\$15,000	\$15,000

#### IN PRACTICE

In this example, as a Managing Consultant 3, you earn a 12% Leadership Match on your Generation 1 Consultants and a 10% match on your Generation 2 Consultants. Qualified Generations are based on Paid-as Ranks, You can I multiple Generation 1 Consultants within a Leg. The Leadersi Match is paid in addition to any other bonuses and commission unight already be earning.





## Leadership Pool

When you are paid as an Executive Consultant 1 or higher, you earn shares of our monthly Leadership Pool. This pool is made from 4% of global monthly CV. You proping shares based on your Patrius Sant.

The total gool amount is divided equally by the total

	SHARES
EXECUTIVE CONSULTANT 1	1
EXECUTIVE CONSULTANT 2	3
EXECUTIVE CONSULTANT 3	5
EXECUTIVE CONSULTANT 4	10
PRESIDENTIAL CONSULTANT	20

ADERSHIP POOL IS CALCULATED MONTHLY

-



#### Nation

- LifeVantage Canada Ltd. is a Direct Sales/Network Marketing compan with a Multi-Level Marketing compensation plan that provides flexibility and opportunity for instructuals to earn extra income based upon selling products to Customers.
- The focus of the LifeVentage Compensation Plan is to pay bonuses and commissions to LifeVantage Consultants based upon their product sales and the product sales of LifeVantage Consultants in their product sales and the product sales of LifeVantage Consultants in their programs.
- Every commission and/or compensation qualification requirement within this LifeVentage Compensation Plan may be achieved througproduct sales to Customers through a Consultant's personal efforts and the effects of the Consultants within their Description.
- LifeVantage products are not sold in retail stores and only licensed.
   Consultants in Good Standing are authorized to self LifeVantage products either directly from their own stock or indirectly through the
- 5. The Consultant Agreement consists of the Life/hantage Compensation and Agreement, the Life/hantage Consultant Application and Agreement, the Life/hantage Policies and Processors. the Life/hantage Polivials Office Agreement (Block Office Agreement, and the Life/hantage Privary Policy and Velebast Live Agreement. The Consultant Agreement agreement the constructual relationship and obligations of each Life/hantage Consultant to Infederation.
- a. A Linewissing of Customer may not personary to nor encourage Customers or other Consultants inventory than each can personally consume an personal Customers each month, in addition, ea Consultant personally agrees that they may not any given month unless 70% of all orders from p
  - A LifeVentage Consultant must disclose the curre Disclosure (TED) when making any earnings or life
- 8. For Leadership Match, if after the individual caps the monthly Leadership Match payout exceed 9% then all monthly Leadership Match earnings will b an equal percentage in order to ensure that the n Match does not exceed 9% of monthly clocks CV.

Notes	
22	





# PROPOSITO. LORDINARIO. A ACTIVADA. A CATIVADA.

#### Contenido

TÉRMINOS CLAVE	4-5
EL CAMINO DEL	
COMPARTIR	
BONIFICACIONES VÍA RÁPIE	A.
CONSTRUIR Y CRECER	
LIDERAR	
AMIRO LEGAL	21

#### **Términos Clave**

#### CTIVO

Se le considere un Consultor Activo cuando su cuenta este en buena, reputación y ha cumpito el requisito de Volumen de Ventas de 130 en ese mes, con un minimo de 40 de Valumen de Ventas Pesponal.

#### VOLUMEN COMISIONABLE (CV)

ci variamen Commonate es a miscolosobre la que se pagen la mayoria de les bonificaciones y comisiones. Cisando ganesan porcentagle de volumer, gane un percentage del VIC de un producto. El vator numérico del VIC de un producto. El vator la teneración de la valume de Vertes por la Tasa PEC, salvo en los rasos en que el VIC.

#### COMPRESION

Proceso por el que el VC de las Comisiones de Nivel se salta a los Consultores inactivos y pasa al siguiente. Consultor Activo.

#### VOLUMEN DE VENTAS DE CLIENTI

El Volumen de Ventas procedente de los necidos de las Chentes

#### LINEA DESCEN

Todos los Consultores petrocinados en su generíogia se consideran parte de su Línea Descendente

#### MEROCINADOR

El Consultor UtleVantage que inscribe a un nuevo Cliente o Consultor También conocido como Patrocinador de Inscripcios.

#### ARBOL DE INSCRIPCION

consecutivamente a través de la inscripción de Consulter y ne por colosación, El Arbot de Inscripción no induse ningun Patrochador de Colocación

#### o our se investe v

siguieres completos.

GENERACIÓN
Los Consultores de su Árbol de Inscripc

Los Consultores de su Arbot de Inscripció con el Reingo Pépado como Consultar. Liber 1 os superior son sus Gerenecores. Una Generación I es el primer Consultar de colouter I fuel Decordente con el Ringa Pepado como Consultor Liber 1 o superior. Una Generación 2 es el siguiente Consultar de sea Periora Con un Ringa Pagado como Consultor Liber 1 o superior. La presentación y al Ringa Pagado como Consultor Liber 1 o superior y ast sicessivamente.

#### BUENA REPUTACIÓN

un Buena reputación significa que cumple el Acuerdo de Consultor, incluido el pago de las cuotas de renovación

#### VOLUMEN DE VENTAS DEL GRUPO

Volumen de Ventas del Grupo es el Volumen de Ventas total suyo y de tod los Cientes y Consultores de todo su

#### PIERNA

Una Pierria comienza con un Consultor de Nivel 1 e induye a todos los Consultores por debajo de 4l. Usted sene tinitas Pierrias como Consultores de Nivel 1.

#### SULTER:

Ellugar que ocupe un Consultor en su Lines Descendente en relación con usited. Todos los Consultores situados directamente debaso de usbad en tu Arbid de Colocación sen su Nivel I, los Consultores situados directamente deba de sus Consultores de Nivel I sen au Nivi 2, y así sucesivamente.

#### REGLA DE VOLUMEN MAXIMO

La cantidad indisma de VVG de cualquer Pierna o de su propio Volumen de Ventas Personal y Volumen de Ventas de Olientes que puede contar para su calificación

#### BAGADO COMO BANGO

Su Payado como Rango ex al Rango pera el que tone derecho cada mes. Su Pagar como Rango defermina muchas de sus bentificaciones. Su Pagado como Rango puede ser igual o inferior a su Pin de Rango dependendo de sus calificaciones monsuales.

#### TASA PEG

El factor de conversión de shistas de Litriunitage. Para establacier la Tapa PEG. Litriunitage revisa periodicamente los lipos de cambio necembra y los lipos de cambio previstos recibidos de sua bancos para lijar un factor de conversió de divisos que normalica los pagos a lo Consustores.

#### VOLUMEN DE VENTAS PERSON

El Volumen de Ventas procedente de l

#### PIN DE RANGO

Su Pin de Rango es su Rango de reconocimiento y es el Rango más año que ha altangado a lo largo de la nuta de Cansultor. Su Pin de Rango está sujetes a reclastificación una vez al año en función de los requisitos de manterimiento de es rango.

#### PATROCINADOR DE COLOCACIÓ

Si codicia a un nuevo Consultator directimiente delegio de usated en si ul lini Descondante, used el se il Patrocinicato de Inscripción y el Patrocinicato de Inscripción y el Patrocinicator de Calcinicatos si embargo, si colocio si un nuevo Consultor debaglo de un Consultar de su Linea Descondante de na l'Arabi del Colocación, sea Consultar de su Linea Descondante se canviviente en ol Patrocinidador de Soliciación de su nuevo artificato.

#### ARBOL DE COLOCAS

Si es Petrocinedor de un Consultor nu puede colocario directamente debejo usted en su Linea Descendente o del de cuarquiere afra posición de Consult su Linea Descendente. Esto se consista Árbol de Colocación, también refesu Linea Descendente o equisio.

#### (OCH)

El Volumen de Venta calificación mensual

AVANCE DE RANG Cuando cumpla los ri ser Pagado como Ra Pin de Range actuiri, Rango superior, y usti

#### VOLUMEN DE VER El valor numérico atri a cada producto com

#### REQUISITO DE VO (SVR)

## de Pagado como Rar LÍNEA ASCENDEN

## La experiencia como Consultor

COMPARTIR Las personas dicen que rustros productos san demasido buenos estapas de la recologió debe pone el enfolias en compartira del fin las primeras atrapas de la recologió debe pone el enfolias en compartira neutros productos de benestar la restrita y el partición, que es vidal para su progresa eletad y por en alla a k su equipo de vertas. Estas vertas en compartira registra de reconspartir con el compartir con estro productos de benestar la restrita y el partición, que es vidal para su progresa eletad y por en alla a k su escapo, por juntos pod con la manera más registad de desentar de senando se respecto y a qualer a va negocio y obtener garana cas rejeidamente.

	CONSULTOR	CONSULTOR 1	CONSULTOR 2	CONSULTOR 3				CONSULTOR LIDER 1	CONSULTOR LIDER 2	CONSULTOR LIDER 3	COMBUITOR	CONSULTOR EJECUTIVO 2	
	0	C1	82	C3	901	162	603	MEX	MC2	MCS	ECT	ecz	601
REQUISITO DE COMPRA PERSONAL	150	150	tso	150	150	150	150	150	150	150	150	150	150
REQUISITO DE VOLUMEN DE VENTAS		150	200	250	300	300	300	300	300	300	300	300	300
VOLUMEN DE VENTAS GRUPAL			500	1,000	2,000	3,500	6,000	10,000	20,000	40,000	80,000	150,000	300,000
REGLA DE VOLUMEN MÁXIMO				750	1,500	2,500	4,000	6.000	10,000	20,000	40,000	67,500	135,000

Cupa	110	
	Compartir. Construir y Liderar.	Crecer.
	Su ruta como Consultor Independiente LifeVantage puede llevario a un mundo de posibilidades.  Empieza por compantir los productos LifeVantage que le encantan con sus Clientes para ayudantes a activat el bienestar y mejorar su saiud. Cuanto más companta, más crecerá al encontrar a otros que quieran unirse a usted en la experiencia do tener un negocio propio.  A medida que avanza en su experiencia como Consultos, empezará a centrarse en capacitar y conducir a los Consultores de su equipo que estén listos para pasar a la siguiente estapa en su camino al évito. En cada etapa evolucionarás sus ganancias, ústed mismo y su vida.	COMO FUNCIONA  Debes cumplir ciertos requisitos de volumen para permanecer áctivo y ganar bonificaciones y Comisiones. Estos requisitos cambaterá, junto con las bonificaciones y Comisiones fatos requisitos cambaterá, junto con las bonificaciones y Comisiones a las que puedes optar, a medida que avances en la ruta y consigas avances de Rango.  A medida que alcances las calificaciones para un Rango específico, se te reconocerá con tur "Pin de Rango" en ese nível mientras permanezcas Activo. Sin embargo, tu "Pagado como Rango" fluctuará con tus calificaciones de mes a mes.



# Compartir.

Compartir su entusiasmo por LifeVantage y vender productos a los Clientes es la esencia de ser Consultor. Además del Beneficio de las Ventas a Clientes, puede ganar sobre el total de ventas mensuales de productos con el Bono de Ventas Personales.

## Beneficio de las Ventas a Clientes

rentre el precio que pagó su Cliente y el precio del Consultor.

EN LA PRACTICA

En estos ejemplos, 2 Clientes hacen un pedicio por el mismo
paquete de productos. El Cliente de la izquierda compre los
productos al precio minorista sin descuento para compras
por unica vez sin INA de MNS2,000. El precio de Consultor
sin INA para ese pedido es de MX31,600. Así, obtene una
ganancia por ventas a clientes (CSP) de MX5400. El Cliente
de la derecha pide los mismos productos en un pedido
de Suscripción por el precio de Suscripción sin INA de
MX51,800. El precio de Consultor sin INA para ese pedido es
de MX51,500. Así, obtene una gananda por ventas a clientes
(CSP) de MX5200.

LA GANANCIA POR VENTAS A CLIENTES (CSP) SE CALCULA DIARIAMENTE





# Compartir. Bono de Ventas Personales

El Bono de Ventas Personales le recompensa por sus comptas personales y sus ventas personales a Clientes. Cuando su Volumen de Ventas Personales (PSV) y su Volumen de Ventas de Clientes (CSV) sumen 500 de SV o más en un solo mes, podrá optar au Bono de Ventas Personales adicional. El bono se paga sobre un porcentaje del CV.

Cuando su PSV y CSV alcancen los 500 de SV en un solo mes, se le reconocerá con un titulo especial antes de su Rango, empezando por Onix a los 500 de SV y cambiando a Esmeralda a los 1000 de SV, Zafiro a los 2000 de SV, y Diamante a partir de los 4000 o más de SV.

EN LA PRÁCTICA

Por ejemplo, si sus Clientes piden productos por valor de 2200 de SV en el mes, puede optar al nivel do bonificación de 15 %. Esta bonificación se paga sobre el CV que tome en cuenta las promociones o descuentos que los Clientes pudieno haber canjeado.

Solo a titulo illustrativo, si la Tasa PEG teórica para México en el momento en que se calcule este bonificación fuera de 20, entonces el importe de la bonificación en la moneda local se calcularia de la siguiente manera:

- Se multiplica el SV por la Tasa PEG teórica para México para obtener el CV. El CV suego se multiplica por el porcentaje de la bonificación que corresponda.
- 2200 SV X 20 (Tasa MX PEG teorica) X 15 % = MX\$6,600.

SV DEL CLIENTE	NIVEL DE BONIFICACIÓN	RE
500 - 905.99	5%	
1,000 - 1,999.98	10%	
2.000 - 1,999.98	15%	
4,000+	20%	





# Consultor

#### Vía del Cliente

Usted gann MX\$1,000 por cada grupo de 3. Clientes elegibles que establèsce durante su Periodo de Via Répida. Un Cliente se convierte en elegible cuando compra productos por valor de al menos 100 S ven en insimo mes natural et que se convierte en Cliente. Para calificar a esta bonificación, tiene que estar Activo en cada un de los mieses en que sus Clientes realicen su primera comora. Calculo basado en US\$50 X 2 (Tasa PEG teórica para M19 - MX\$1,000).



LA VÍA DEL CLIENTE SE CALCULA SEMANALMENTE

#### 22 Vía del Consultor

Ganas ™\$1,000 por cada grupo de 3 Consultore que patriorines durante su Periodo de Via-Rapida. Para calificar a esta bonificación, tienes que estar Activo cada mes que se inscriban tus Consultores, y cada Consultor debe estar Activo en el mise na que se inscriban. Cálculo basado en ™\$50 X 20 (Tasa MX PEC téórica) = ™\$1,000



#### JELIGE LA VÍA PÁPIDAL

Estas bonificaciones pueden impulsarlo desde el principio. Su Periodo de Vía Rápida comienza el día en que se inscribe como Consultor y continúa durante los anueses naturales siguientes.

## 93 Vía de Avance de Rango

Cuando alcance el Rango de Consultor Sénior 1 por primera vez durante su Periodo de Vía Rápida, ganará una bonificación de Avance de Rango de MX\$2.000. Cálculo basado en US\$100 X 20 (Tasa PEG teórica para MXI = MX\$1.000.

> LA VIA DE AVANCE DE RANGO SE CALCULA MENSUALMENTE

#### º4 Vía Aceleradora

Cuando consiga cualquiera de las bonificaciones de la Via Rápida antes del final de su primer mes natural completo como Consultor, ganará una bonificación de MX\$1,000. Cálculo basado en U\$\$50 X 20 Tibro BGC frotiere pera MI. - MX\$1,000.



Cuando asciencies al Rango de Cuando consiga cualculo.

CONSULTOR SÉNIOR 1 de las benificaciones de la Discolar antes del final de

LA VÍA ACELERADORA SE CALCULA MENSUALMENTE



# Patrocinador

EL PATROCINADOR
DE INSCRIPCIÓN GANA \*\*\$1,000



# Gana cuando ayude a otros a ganar en la Vía Rápida

Los primeros meses del Negocio del Consultor son cruciales para establecer un futuro de éxito. Como su Patrocinador, trabaja estrechamente con ellos durante su Periodo de Vía Rápida para ayudarles a empezar bien y, además, podrá ganar bonificaciones.

## Bonificación de Mentor

Para recibir cualquier Bonificación de Mentor, debe estar Activo en el mes en que su nuevo Consultor cumpla los requisitos. Gana un 15 % del CV de todos sus Consultores nuevos por sus ventas a Clientes durante su Periodo Fast Track.



15% DE CV

LA BONIFICACION DE MENTOR SE CALCULA MENSUALMENTE

#### EN LA PRÁCTICA

EN LA PRACTICA
En este ejemplo, si su Consultor reclén patro
SV durante su Periodo de Via Rápida, obtien
del 15 %, Solo a titulo illustrativo, si la Tisas Pér
México en el momento en que se calcula est
de 20, entonces el importe de la bonificación
calcularia de la siguiente manera:

- 500 SV X 20 (Tasa PEG teórica para MX



PPR SVR GSV MVR NIVEL 1

NIVEL 2 NIVEL 3

NIVEL 4

NIVEL 5

NIVEL 6

NIVEL 7 NIVEL B

NIVEL 9

omisiones de Nivel por construir su equipo y enseñar a los que patrocina a crear sus propios equipos fuertes. Como tor Activa, se le paga un porcentaje de comisiones del CV de les ventas de su equipo. Su nivel de Pagado como deline los porcentajes que gana y el número de niveles en los que puede recibir comisiones.

Todos los Consultores directamente por debajo de usteden su Arbol de Colocación son su Nivel 1. A los Consultores se les paga el Beneficio de las Ventas a Clientes y el Bono de Ventas Personales por las compras de sus Clientes inscritos personalmente. Los Patrocinadores no pueden percibir Comisiones de Nivel por sus Clientes personales. Las comisiones de Nivel por sus Clientes personales. Las comisiones de Nivel por sus Clientes

	CONSULTOR 1	CONSULTOR 2					CONSULTOR LIDER 1	CONSULTOR LIDER 2	CONSULTOR LIDER 3	COMBULTOR	CONSULTOR EJECUTIVO 2			
	C1	Ca					MCY		MCS					
40	40	40	40	40	40	40	40	40	40	40	40	40	40	40
	150	200	250	300	300	300	300	300	300	300	300	300	300	300
		500	1,000	2,000	3,500	6,000	10,000	20,000	40,000	80,000	150,000	300,000	600,000	1,000,000
		-	750	1,500	2,500	4,000	6,000	10,000	20,000	40,000	67,500	135,000	270,000	450,000
	5%	7%	9%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%
			3%	5%	6%	75	7%	7%	3%	75	7%	7%	7%	-2%
					2%	5%	6%	7%	7%	7%	7%	75	7%	7%
						3%	5%	6%	-6%	6%	8%	6%	6%	6%
							3%	8%	6%	6%	6%	6%	6%	6%
								3%	4%	5%	55	5%	5%	5%
								25	45	4%	4%	45	4%	45
									35.	3%	3%	3%	3%	3%
									3%	3%	3%	3%	3%	-35

#### Compresión Activa

Proceso por el que el CV de las Comisiones de Nivel se salta a los Consultores inactivos y pesa al siguiente Consultor Activo

#### EN LA PRÁCTICA

Este ejempio muestra cómo el volumen podrá hacer Roll-Up en una Piema de un equipo. Usade es un Consulto Schoino 3 de Nivel 5 por encima del Consultor que obtuvo el volumen. Si empieza por la parte inheior del gráfico, verá cómo el Coffico, verá cómo el Volumen por encima y por debajo de usted.

#### CLAVE

Califica (se paga) No califica (no se paga) Inactivo (sube)





## Bono de Igualación de Liderazgo

Cuando cobre como Consultor Líder 2 o superior en el mes, podrá recibir un Leadership Match sobre las Generaciones calificadas.

El bono Leadership Match se paga sobre las comisiones de nivel de sus Generaciones calificadas.

#### CÓMO FUNCIONAN LAS GENERACIONES

Su Generación 1 es el primer Consultor de cualquier Pierna de su equipo con un Pagado como Rango de Consultor Lider 1 o superior. Una Generación 2 es el siguiente Consultor de esa Pierna con un Rango Pagado como Consultor Lider 1 o superior, y así sucesivamente.

Sólo a titulo ilustrativo, si la Tasa PEG teórica para México en el momento en que se calcula esta bosificación fuera de 20, entonces el Limite por Igualación en moneda local se calcularía de la siguiente manera:

- El límite por igualación en dólares americanos se multiplica por la tasa PEG teórica para MX.
- Por ejemplo, el limite por igualación para un Consultor Lider 2 seria de USD\$1,000 X 20 (tasa PEG teórica para MX) = MX\$20,000.

EL BONO DE IGUALACIÓN DE LIDERAZGO SE CALCULA MENSUALMENTE

EL BONG DE IGUALACIÓN DE LIDERAZGO MENSUAL PUEDE PAGAR HASTA UN MÁXIMO DEL 9 % DEL CV GLOBAL MENSUAL


18

Cuando alcance el nivel de Líder, habrásprobado que realmente entiende lo que se necesita para tener éxito y que dispones de las habilidades necesarias para ayudar a orientar y motivar a otros. No dejede nutrir a sus futuros líderes y de ayudarles a progresar y podrá obtener importames bonificaciones por formar un equipo tan sólido.

ente.	COMSULTOR LÍDER 2	COMSULTOR LÍDER 3					CONSULTOR
GENERACIÓN 1	7%	12%	15%	20%	20%	20%	20%
GENERACIÓN 2		10%	12%	15%	20%	20%	20%
GENERACIÓN 3			10%	12%	15%	20%	20%
GENERACIÓN 4				10%	12%	15%	20%
GENERACIÓN 5					10%	12%	15%
GENERACIÓN 6						10%	12%
GENERACIÓN 7							12%
LÍMITE POR IGUALACIÓN	\$1,000	\$2,500	\$5,000	\$7,500	\$10,000	\$15,000	\$15,000

#### EN LA PRÁCTICA

En este ejemplo, como Consultor Líder 3, gana un bono Leadership Match del 12 % en sus Consultores Generación 1 y un 10 % en sus Consultores Generación 2. Las Generaciones calificadas se basan en lo Pagado com Puedetener varios Consultores de Generación 1 dentro d bono Leadership Match se paga de forma adicional a otra comisiones que ya puede estar ganando.



# Liderar.

## Fondo de Bonos de Liderazgo

obtieneparticipaciones de nuestro Leadership Pool mens Este fondo se compone del 4 % del CV mensual global. Recibe participaciones en función de su nivel de Pagado

El importe total del fondo común se divide a partes iguales entre el número total de participaciones mensuales que ganan los Consultores.

	J. 100 C.
CONSULTOR EJECUTIVO 1	
CONSULTOR EJECUTIVO 2	
CONSULTOR EJECUTIVO 3	
CONSULTOR EJECUTIVO 4	10
CONSULTOR PRESIDENCIAL	20



#### Notificaciones

- Notificas

  1. LifeVinitige de México S, de R.L. de C.V. es una empresa de Veritas
  Directos Mercados en Redes con un plan de componisación de
  Mercados Multimed que ordere familitario de productos
  a Clamas.

  2. El confesso de Plan de Componisación de LifeVinitago en separ
  bonificaciónes y Consistense a las Consultanos LifeVinitago en base
  a su aventas de production y las veretas de sublectos LifeVinitagos en base
  a su aventas de production y las veretas de production de los Consultanos
  es un aventa de production y las veretas de production de los Consultanos
  LifeVinitago en su ecupio de material personal monificiale y selo
  los Consultanos con licercia y Buena requisión están autoritación a
  a vende production LifeVinitago, no su uniden os selos de los compos en
  linea de la empresa en evenificant de las compra en
  linea de la empresa en evenificant de la Componisación de
  LifeVinitago Lis Sociitad y Acuerdo de Consultar de LifeVinitago, las
  Politicas y Procedimientos de LifeVinitago, el Acuerdo de Oficia
  Pulsa de la lemprisago Acuerdo de LifeVinitago, las
  Politicas y Procedimientos de LifeVinitago, el Acuerdo de Oficia
  Princidad de LifeVinitago de LifeVinitago, el Publica de
  Princidad de LifeVinitago y el Acuerdo de Los de Segue Vinita
  B. Acuerdo de Consultar y la Pestica comunitar de Política de
  Princidad de LifeVinitago y el Acuerdo de Los de Segue Vinita
  B. Acuerdo de Consultar y la Pestica comismo personalmente pora
  simismo na animar a Clarifeso u dos Consultaros a compora más
  inisteno na animar a Clarifeso u dos Consultaros a compora más
  inisteno na animar a Clarifeso u dos Consultaros a compora más
  inisteno na animar a Clarifeso u dos Consultaros a compora más
  inisteno na animar a Clarifeso u dos Consultaros a compora más
  inisteno na animar a Clarifeso u dos Consultaros a comporamento y lo
  consultar de la compo de consultar per la rediccio consultaros per los de consultaros de los de consultaros de los de consultaros de los de las de las delicios de los meses anteriores hayan sido vendidos o consumidos
  a través

Notas	
22	





TRASE. Life. It's complicated. Wessy, Beautiful: It goes by first, and you want to live life to the goes by first, and you want to live life to the goes by first. If you want to live life to the goes by first, and you want

IT'S TIME TO LIVE WITH PURPOSE.
IT'S TIME TO INSPIRE REMARKABLE.
IT'S TIME TO LIVE ACTIVATED.

## Table of Contents

WELCOME	
KEY TERMS	45
THE CONSULTANT PATH	6-7
SHARE	
FAST TRACK BONUSES	
BUILD & GROW	
LEAD	
LEGAL NOTICE	

## Key Terms

#### ACTIVE

You are considered an Active Consultant when your account is in Good Standing and you have met the ISO Sales Volume. Requirement in that menth, with at least 40 Personal Sales Volume.

COMMISSIONABLE VOLUME (CV)
Commissionable Volume is the measurement on which most bonuses

and commissions are paid. When you cam a percentage of a products CV. The numeric value for CV is syncarly obtained when Sales. Volume is multiplied by the PEG. Rate, except in cases where CV has been decounted for automatic value for CV in as cases.

#### COMPRESSION

Commissions skips inactive Consultants and rolls up to the next Active Consultant

#### \_\_\_\_

All of the Consultants sporwored into your genealogy are considered part of

#### MENTALES

The LifeVentage Consultant who enrols a new Customer or Consultant. Also known

#### ENROLLMENT TREE

not by pracement. The Enrollment Tree does not include any Placement Sportso

Consultants in your Enrollment Tree with the Piedus Bank of Managaing Consultant to higher are your Generations. A Generation 1 is the first Consultant in any downline with a Piedus Revice of Managain Consultant 1 on higher. A Generation 2 is the next Consultant in that Log with a Paid as Rank of Managaing Consultant 1 on higher, and so on.

#### COOR STANDING

Good Stending means you are in compliance with the Consultant Agreement, including payment of any applicable renewal fees.

#### GROUP SALES VOLUME (GSV)

Group Sales Volume is the total Sales
Volume from you and all the Customer
and Consultants in your entire team.

#### LEG

A Leg begins with a Level 1 Consultant and includes all of the Consultants beneath them. You have as many Legs as you have Level 1 Consultants.

#### .....

The location a Consultant has in your downline in relation to you. All of the Consultants directly below you in your Placement Ties are your Level 1. Consultants placed directly below you Level 1 Consultants placed directly below you Level 1 Consultants placed directly below you are on.

#### MAXIMUM VOLUME RULE (MVR

The maximum amount of GSV from any one Leg or from your own Personal Sales Volum and Customer Sales Volume that can count Vessel your monthly Rayle mail for all on

#### AID-AC DANK

Your Paid-as Rank is the Rank for which you qualify each month. Your Paid-as Rank determines many of your bonuses. Your Paid-as Rank may be the same as or lowe than your Pin Rank depending on your monthly qualifications.

#### PEG RATE

The Labelantage foreign currency conversion factor. To establish the PEG Rate, University and additional performance and projected foreign exchange rates and projected foreign exchange rates received from its banks to set a foreign currency conversion factor that normal executions from Computation.

## PERSONAL SALES VOLUME (PSV) The Sales Volume originating from your

#### PIN RANK

Your Pin Rank is your recognition Rank and is the highest Rank you have schieve along the Consultant Path. Your Pin Rank is subject to reclassification once per yer based on the maintenance requirements for their con-

#### AL CONTROL CONTROL

If you place a new Consultant directly below you in your downline, you are the Enrollment Sponsor and Placement Sponsor. However, if you place a new Consultant below a downline Consultant in the Placement Tree, that downline Consultant becomes your new enrolleer's

#### DI ACCMENTADO

If you are a new Consultant's Enroller, may place them directly below you in a downline or under any other downline Consultant's position. This is consider your Placement Tires, also referred to a your downline or boars.

## The Sales Volume th

RANK ADVANCIN
When you meet the opeid as a Rank highe

#### Pin Rank, you will \*a Rank, and your Pin I reflect that new mile


The numeric value at LifeVantage to each product sold and/or of

#### SALES VOLUME RI The accumulation of Sales Volume and yo

#### Sales Volume and yo Volume to meet your requirement.

## UPLINE

All of the Consultants Enrollment and/or Pk



## The Consultant Path

SHARE People say our products are too good not to shared in the early stages of your business, begin with a strong emphasis on sharing our welmess products by selling our selliness seals are the factored with the strong emphasis on sharing our welmess products by selling our selliness selling and soundering, which is vital to your continued growth. The larget you grow together you can enjoy the resistance when the product is to the product of the selling of the product is to the product of the product of the product is to the product of the product

	a CONSULTANT	2 CONSULTANT 1	2 CONSULTANT 2					E MANAGING 9 CONSULTANT.1	E MANAGING CONSULTANT 2	S MANAGING CONSULTANT 3		EXECUTIVE COMSULTANT 2	EXECUTIVE COMBULTANT 3
PERSONAL PURCHASE REQUIREMENT		40	40	40	40	40	40	40	40	40	40	40	40
SALES VOLUME REQUIREMENT		150	200	250	300	300	300	300	300	300	300	300	300
GROUP SALES VOLUME			500	1,000	2,000	3,500	6,000	10,000	20,000	40,000	80,000	150,000	300,000
MAXIMUM VOLUME RULE				750	1,500	2,500	4,000	6,000	10,000	20,000	40,000	67,500	135,000

0		
11-0	11101	
	Share.	
	Snare.	
	Build & Gro	
		A CONTRACTOR OF THE STATE OF TH
	Lead.	A STATE OF THE STA
	Your path as an Independent LifeVantage Consultant can lead to a world of possibilities, Start	HOW IT WORKS You must meet certain volume requirements to
	by sharing the LifeVantage products that you love	stay Active and earn bonuses and commissions.
	with Customers to help them activate wellness	These requirements will change, along with
	and improve their health. The more you share, the	the bonuses and commissions you can qualify
	more you'll grow as you find others who want to	for, as you move along the path and earn Rank
	join you on the path with a business of their own.	advancements.
	As you progress along the Consultant Path,	As you reach the qualifications for a specific Rank,
	your attention will shift to building and leading	you will be recognized with your "Pin Rank" at that
	Consultants on your team who are ready to grow	level for as long as you remain Active. However,
	to the next stage of success. At every stage you'll	your "Paid-as Rank" will fluctuate with your
	evolve your earnings, yourself, and your life.	qualifications from month to month.



# Share.

Sharing your excitement about LifeVantage and selling products to Customers is at the heart of being a Consultant. In addition to Customer Sales Profit, you can earn up to 20% on total monthly product sales with the Personal Sales Bonus.

## Customer Sales Profit

Customer Sales Profit allows you to earn commissions on every order. Here's how it works: When your Customers order LifeVentage products, you earn the difference between the price your Customer paid and the Consultant price.

#### IN PRACTICE

IN PRACTICE

In these examples, 2 Customers are ordering the same set of products. The Customer on the left purchases the products at the full VAT-exclusive One Time Retail poice of £75. The VAT-exclusive Consultant price for that order is £60. So, you earn a Customer Sales Profit of £15. The Customer on the right orders the same products on a Subscription order for the VAT-exclusive Subscription price of £675.0. The VAT-exclusive Consultant price for that order is £60. So, you earn a Customer Sales Profit of \$750.

275 PURCHASE 26 PRICE Subtract 250 CONSULTANT PRICE

It is important to one that while the published prices may be inclusive of Vision Added Tax (NAT), all bonuses and/or commissions are paid on VAT-exclusive visit.

"May be disturbed three business stays after the formul calculation date to quarted Commissions also are in an eligible market and have reached the Pin Rank of

"Procuration to white "Procurations" are not exceeded to the state of the conditions are not an eligible market and have reached the Pin Rank of

"Procuration to white "Procurations" are not exceeded to the state of the conditions are not exceeded to the Pin Rank of

CUSTOMER SALES PROFIT IS CALCULATED DAILY



# Share.

## Personal Sales Bonus

The Personal Sales Bonus rewards you on your personal Custome sales. When your Customer Sales Volume (CSV) totals 500 SV or more in a single month, you become eligible for an additional Personal Sales Bonus. The Bonus is peid on a percentage of CV.

When your CSV reaches 500 in a single month, you will be recognized with a special title before your Rank, starting with Onyx at 500 SV then changing to Emerald at 1000 SV, Sapphire at 2000 SV, and Diamond at 4000 SV and higher

## IN PRACTICE

For example, if your Customers order 2200 SV worth of products in the month, you are eligible for the 15% bonus tier. This bonus is paid on CV which takes into account promos or discounts Customers may have redeemed.

CUSTOMER	BONUS	RECOGNITION TITLE
500 - 999.99	6%	ONYX
1,000 - 1,999,99	ton	EMURALO
2,000 - 3,999.99	ISN	SAPPHIRE
4.000+	20%	DIAMOND

For illustration purposes only, if the theoretical PEG Rate for the UK at the time this bonus is calculated were .75, then the bonus amount in local currency would be calculated as follows:

- 2200 SV X .75 (theoretical UK PEG F £247.50.



£247.50 PERSONAL SALES BONUS and the title of

SAPPHIRE



# Consultant









CUSTOMER TRACK IS CALCULATED WEEK

## 02 Consultant Track





These bonuses can boost you right from the start. Your Fast Track Period begins the day you enroll as a Consultant and continues through the next 3 calendar months.

## 93 RankAdvancementTrack

## **94** Accelerator Track



#### YOU EARN £75

When you advance to the Rank of SENIOR CONSULTANT 1





# Enroller

## 91 Rank Advancement Track

ENROLLER EARNS £37.50

## 92 Accelerator Track



#### ENROLLER EARNS £18.75

# **Earn When** You Help Others Win on The Fast Track

The first few months of a new Consultant's business are critical to setting them up for a future of success. As their Enroller, work closely with them during their Fast Track Period to help them get started right and you could

#### **Mentor Bonus**

To receive any Mentor Bonus, you must be Active in the month your new Consultant qualifies. Earn 15% of all your new Consultant's CV from their Customer sales during their Fast Track Period.



You earn 15%

£56.25 MENTOR BONUS MENTOR BONUS IS CALCULATED MONTHLY

#### IN PRACTICE

In this example, if your newly enrolled Cons SV during their Fast Track Period, you earn. For illustration purposes only, if the theorets the UK at the time this bonus is calculated a the bonus amount in local currency would b follows:

SV is multiplied by the theoretical UK P
the CV, CV is then multiplied by the app

500 SV X .75 (theoretical UK PEG Rate) X 15



## **Level Commissions**

You earn Level Commissions for building your team and teaching those you sponsor to create strong teams of their own. As an Active Consultant, you are paid a percentage of commissions from the CV of your team's sales. Your Paid as Rank determines the percentages you earn and the number of levels on which you are eligible to receive a commission.

HOW LEVELS WORK
All of the Consultants directly below you in your Placement Tree are your Level 1. Consultants are paid Customers
Sales Profit and Personal Sales Bonus on their personally enrolled Customer purchases. Enrollers are not eligible
for a Level Commission on their personal Customers. Levels commissions ARE CALCULATED MONTHLY

	n CONSULTANT	2 CONSULTANT (	2 CONSULTANT 2					E MANAGING CONSULTANT 1	managing Consultant 2	R MANAGING CONSULTANTS		EXECUTIVE CONSULTANT 2			PRESIDENTIAL CONSULTANT
PPR	40	40	40	40	40	40	40	40	40	40	40	40	40	40	40
SVR		150	200	250	300	300	300	300	300	300	300	300	300	300	300
GSV			500	1,000	2,000	3,500	6,000	10,000	20,000	40,000	30,000	150,000	300,000	600,000	1,000,000
MVR				750	1,500	2,500	4,000	6,000	10,000	20,000	40,000	67,500	135,000	270,000	450,000
LEVEL 1		5%	7%	9%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%
PEART 5				3%	5%	6%	75	7%	7%	75	75	7%	7%	7%	-2%
<b>TEAET 3</b>						2%	5%	G%.	7%	7%	7%	7%	7%	7%	7%
LEVEL 4							3%	5%	6%	-6%	6%	6%	6%	6%	6%
LEVEL 5								3%	S%	6%	6%	6%	6%	6%	6%
LEVEL 6									3%	45	5%	55	5%	5%	5%
LEVEL 7									25	45	4%	4%	45	4%	4%
LEVEL 8										35	3%	3%	3%	3%	3%
LEVEL 9										3%	3%	3%	3%	3%	-3%

## Active Compression

A process by which CV for Level
Commissions skips inactive Consultants
and rolls up to the next Active Consultant.

#### IN PRACTICE

KEY

Qualified (Paid)

Not Qualified (Not Paid)

Inactive (Rolls Up)

This example shows how volume could roll up in one Leg of a team. You're a .
Senior Consultant 3 at Level 5 above the Consultant who earned the volume. Starling from the bottom of the chart, you see how CV flows up and what happens below and above you.





## Leadership Match

When you are paid as a Managing Consultant 2 or higher in the month, you can receive a Leadership Match on qualified Generations.

The Leadership Match is paid on your qualified Generations' Level

#### HOW GENERATIONS WORK

Your Generation 1 is the first Consultant in any Leg in your feam with a Pold-as Rank of Managing Consultant 1 or higher. A Generation 2 is the next Consultant in that Leg with a Pold-as Rank of Managing Consultant 1 or higher, and so on.

GENERATION 2 GENERATION 3

GENERATION 5

GENERATION 7

CAP PER MATCH

For illustration purposes only, if the theoretical PEG Rate for the UK at the time this bonus is calculated were .75, then the Cap Per Match in local currency would be calculated as follows:

Cap Per Match amount in US\$ is multiplied by the theoretical UK PEG Rate.

For example, the Cap Per Match for a Managing Consultant 2 would be US\$1,000 X .75 (theoretical UK PEG Rate) = £750,

MONTHLY LEADERSHIP MATCH CAN PAYOUT UP TO A MAXIMUM OF 9% OF MONTHLY GLOBAL CV.


When you reach the Leader level, you've shown you truly know what it takes to succeed and have the skills to help mentor and motivate others. Keep cultivating your future leaders and helping them grow and you can earn substantial bonuses for building such a strong team.

MANAGING CONSULTANT 2	MANAGING CONSULTANT 3	EXECUTIVE CONSULTANT 1	EXECUTIVE CONSULTARE 2	EXECUTIVE COMSULTANT 3	EXECUTIVE CONSULTANT 4	PRESIDENTIAL
75.	12%	15%	205	20%	20%	20%
	10%	12%	15%	20%	20%	20%
		10%	12%	15%	20%	20%
			10%	12%	15%	20%
				10%	12%	15%
					10%	12%
						12%
\$1,000	\$2,500	\$5.000	\$7,500	\$10,000	\$15,000	\$15,000

#### IN PRACTICE

In this example, as a Managing Consultant 3, you earn a 12% Leadership Match on your Generation 1 Consultants and a 10% match on your Generation 2 Consultants.

Qualified Generations are based on Paid-as Ranks. You c multiple Generation 1 Consultants within a Leg. The Lead Match is paid in addition to any other bonuses and commyou might already be earning





## Leadership Pool

When you are paid as an Executive Consultant 1 or higher, you earn shares of our monthly Leadership Pool. This pool is made from 4% of global monthly CV. You receive shares based on your Peid-as Rank.

The total pool amount is divided equally by the total

	SHARES
EXECUTIVE CONSULTANT 1	*
EXECUTIVE CONSULTANT 2	ž
EXECUTIVE CONSULTANT 3	5
EXECUTIVE CONSULTANT 4	10
PRESIDENTIAL CONSULTANT	20

ADERSHIP POOL IS CALCULATED MONTHLY



## Notices

- LifeVantage Netherlands BV. is a Direct Sales/Network Marketing company with a Multi-Level Marketing compensation plan that provides/billy and opportunity for individuals to earn extra income based upon selling apoducts to Customers.
- The focus of the LifeVentage Compensation Plan is to pay bonuses and commissions to LifeVentage Consultants based upon their product sales and the product sales of LifeVentage Consultants in their personal makesing name to utilize and using Contention.
- LifeVantage products are not sold in retail stores and only licensed.
   Consultants in Good Standing are authorized to sell LifeVantage products either directly from their own stock or indirectly through the company's poline shopping cost at www.ilfevantage.com.
- 4. The Consultant Agreement consists of the LithVantage Compensation Plan, the LiteVantage Consultant Application and Agreement, the LiteVantage Policies and Procedures, the LiteVantage Virtual Office Agreement (Back Office Agreement, and the LiteVantage Privacy Policy and Webbel Use Agreement. The Consultant Agreement governs the contractual relationship and obligations of each LiteVantage Consultant to History.
- A LifeVantage Consultant may not personally purchase for themse nor encourage Customers or other Consultants to purchase more inventory than each can personally consume and/or sell to their
- Consultant personally agrees that they may not a any given month unless 70% of all orders from p
- 5. The Consultants sales earnings disclosed are pot earnings and not net of other business expenses representative of the actual income, if any, that o will earn through the LifeVantage Compensation I earnings will depend on the individual dispence, market conditions. LifeVantage does not guarants
- Beginning on 1 February 2024 no new Business C allowed, and all existing Business Centres, wheth will be terminated and will not be reinstated. Any
- 8. Beginning on February 1, 2024, a fam
- For Leadership Match, if after the individual caps, the monthly Leadership Match payout exceed 9% then all monthly Leadership Match earnings will b an equal percentage in order to ensure that their Match does not exceed 9% of monthly clocker CV.

Notes	
23	






APOSE. Life. It's complicated Messy. Beautiful. It goes by first, and you want to live life to the scale discondibilities longer, or work lower part time or full-time.

IT'S TIME TO LIVE WITH PURPOSE.
IT'S TIME TO INSPIRE REMARKABLE.
IT'S TIME TO LIVE ACTIVATED.

WELCOME	
KEY TERMS	
THE CONSULTANT PATH	
FAST TRACK BONUSES	
BUILD & GROW	
LEAD	
LEGAL NOTICE	

### Key Terms



### The Consultant Path

SHARE People say our products are too glood not to lithered in the early stapes of your business, begin with a strong emphasis on sharing our welfness products by selling our welfness products by selling our welfness products by selling our sellness and see a specity profit.

BUILD & GROW By the time you reach Senior to to your name. Teach by example successful Life/Arrespe busines with a strong emphasis on sharing our selliness products by selling our selliness selling and sponnesting, which is successful Life/Arrespe business our welfness products by selling our selliness products by selling to the selling and sponnesting, which is concurring, and if it your same together you can enjoy the results and see a specity profit.

	a CONSULTANT	2 CONSULTANT 1	2 CONSULTANT 2	2 CONSULTANT 3	SENIOR CONSULTANT I	E SENIOR CONSULTANT 2	S SENIOR COMBUSTANT 3	R MANAGING F CONSULTANT.1	E MANAGING CONSULTANT 2	S MANAGING CONSULTANT 3	EXECUTIVE CONSULTANT 1	EXECUTIVE CONSULTANT 2	EXECUTIVE COMBULTANT 3
PERSONAL PURCHASE REQUIREMENT		40	40	40	40	40	40	40	40	40	40	40	40
SALES VOLUME REQUIREMENT		150	200	250	300	800	300	300	300	300	300	300	300
GROUP SALES VOLUME			500	1,000	2,000	3,500	6,000	10,000	20,000	40,000	80,000	150,000	300,000
MAXIMUM VOLUME RULE				750	1,500	2,500	4,000	6,000	10,000	20,000	40,000	67,500	135,000

0		
NO	ve.	
	Share.	AMILE
	<b>Build &amp; Gro</b>	w
	Lead.	
	Your path as an independent LifeVantage Consultant can lead to a world of possibilities, Start by sharing the LifeVantage products that you love with Customers to help them activate wellness and improve their health. The more you share, the more you'll grow as you find others who want to join you on the path with a business of their own.	HOW IT WORKS  To stay Active and earn bonuses and commissions.  These requirements will change, along with the bonuses and commissions you can qualify for, as you move along the path and earn Rank advancements.
	As you progress along the Consultant Path, your attention will shift to building and leading Consultants on your team who are ready to grow to the next stage of success. At every stage you'll evolve your earnings, yourself, and your life.	As you reach the qualifications for a specific Rank, you will be recognized with your "Pin Rank" at that level for as long as you remain Active. However, your "Paid-as Rank" will fluctuate with your qualifications from month to month.



## Share.

Sharing your excitement about LifeVantage and selling products to Gustomers is at the heart of being a Consultant. In addition to Customer Sales Profit, you can earn up to 20% on total monthly product sales with the Personal Sales Bonus.

### Customer Sales Profit

Customer Sales Profit allows you to earn commissions on évery order. Here's how it works: When your Customers order LifeVantage products, you earn the difference between the price your Customer paid and the Consultant price.

In PRACTICE
In these examples, 2 Customers are ordering the same set of products. The Customer on the left purchases the products of the full VIAT-exclusive One Time Retail price of 500. The VAT-exclusive Consultant price for that order is 672. So, you earn a Customer Sales Profit of 618. The Customer on the right orders the same products on a Subscription order for the VAT-exclusive Subscription price of 681. The VAT-exclusive Subscription price of 681. The VAT-exclusive Consultant price for that order is 672. So, you earn a Customer Sales Profit of 69.

e90 PURCHASE e81
PRICE
Subtract
E72
CONSULTANT
PRICE

CUSTOMER SALES PROFIT IS CALCULATED DAILY

It is imposter to may that while the published prices may be inclusive of Value Added Tax (NAT), at boruses and/or commissions are paid on VAT-exclusive with Yally be distursed mee business days that the forms colsulation does to quartied Computers who over an entities market and have reached the Fri Rink'd Computers who over an entities of the reached the Fri Rink'd Computers who over an entitle remark and have reached the Fri Rink'd Computers and the Computer State (Indiana) and the Compu



# Share.

### Personal Sales Bonus

The Personal Sales Bonus rewards you on your personal Customer sales. When your Customer Sales Volume (CSV) totals 500 SV or more in a single month, you become eligible for an additional Personal Sales Bonus. The Bonus is paid on a percentage of CV.

When your CSV reaches 500 in a single month, you will be recognized with a special title before your Rank, starting with Onyx at 500 SV then changing to Emerald at 1000 SV, Sapphire at 2000 SV, and Diamond at 4000 SV and higher

For example, if your Customers order 2200 SV worth of products in the month, you are eligible for the 15% bonus tier. This bonus is paid on CV which takes into account promos or discounts Customers may have redeemed.

CUSTOMER	BONUS	RECOGNITION TITLE
500 - 999.99		
1,000 - 1,999,99	tos	EMERALD
2,000 - 3,999.99	ISN	SAPPHIRE
4.000+	20%	DIAMOND

- 2200 SV X .90 (theoretical EU PEG I



you earn
15%
of CV

C297
PERSONAL
SALES BONUS
and the title of

SAPPHIRE



## Consultant



02 Consultant Track

## 93 RankAdvancement Track

### 04 Accelerator Track

These bonuses can boost you right from the start. Your Fast Track Period begins the day you enroll as a Consultant and continues through the next 3 calendar months.









CUSTOMER TRACK IS CALCULATED WEEK





When you advance to the Rank of SENIOR CONSULTANT 1





## Enroller

### 21 Rank Advancement Track

ENROLLER EARNS €45

### 02 Accelerator Track



### ENROLLER EARNS €22.50

## **Earn When** You Help Others Win on The Fast Track

The first few months of a new Consultant's business are critical to setting them up for a future of success. As their Enroller, work closely with them during their Fast Track Period to help them get started right and you could

### **Mentor Bonus**

To receive any Mentor Bonus, you must be Active in the month your new Consultant qualifies. Earn 15% of all your new Consultant's CV from their Customer sales during their Fast Track Period.



You earn

€67.50 MENTOR BONUS MENTOR BONUS IS CALCULATED MONTHLY

IN PRACTICE In this example. If your newly enrolled Cons. SV during their Fast Track Period, you earn For illustration purposes only, if the theoreti the EU at the time this bonus is calculated of the bonus amount in local currency would be follows:

SV is multiplied by the theoretical EU Pi the CV. CV is then multiplied by the app percentage.

500 SV X .90 (theoretical EU PEG Rate) X 15



### **Level Commissions**

You earn Level Commissions for building your team and teaching those you sponsor to create strong teams of their own. As an Active Consultant, you are paid a percentage of commissions from the CV of your team's sales. Your Paid as Rank determines the percentages you earn and the number of levels on which you are eligible to receive a commission.

HOW LEVELS WORK
All of the Consultants directly below you in your Placement Tree are your Level 1. Consultants are paid Customers
Sales Profit and Personal Sales Bonus on their personally enrolled Customer purchases. Enrollers are not eligible
for a Level Commission on their personal Customers. Level commissions ARE CALCULATED MONTHLY

	CONSULTANT	CONSULTANT	CONSULTANT 2		SENIOR CONSULTANT 1			MANAGING CONSULTANT 1	MANAGING CONSULTANT 2	MANAGING CONSULTANT 3		EXECUTIVE CONSULTANT 2			PRESIDENTIAL
2.50	c	C1	C3	C3	SEE	500	363	MC1	HC2	MC3	101	ECS	0.03	104	PCI
PPR	40	150	200	40 250	300	40 300	40 300	300	40 800	40 300	40 300	300	40 300	300	300
GSV		180	500	1,000	2.000	3,500	6,000	10,000	20,000	40,000	80,000	150,000	300,000	600,000	1.000,000
MVR				750	1,500	2,500	4,000	6,000	10,000	20,000	40,000	67,500	135,000	270,000	450,000
LEVEL 1		5%	2%	9%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%
LEVEL 2				3%	5%	6%	75	7%	7%	75	75	7%	75	7%	7%
PEAET 3						2%	5%	6%	7%	75	7%	7%	75	7%	7%
LEVEL 4							3%	5%	- 6%	65	6%	8%	6%	6%	6%
LEVEL 5								3%	SX	65	6%	6%	6%	6%	6%
LEVEL 6									3%	4%	5%	55	5%	5%	5%
LEVEL 7									25	45	4%	4%	45	4%	45
<b>LEVEL 8</b>										35	3%	3%	3%	3%	3%
LEVEL 9										3%	3%	3%	3%	3%	3%

### Active Compression

A process by which CV for Level
Commissions skips inactive Consultants
and rolls up to the next Active Consultant.

### IN PRACTICE

KEY

Qualified (Paid)

Not Qualified (Not Paid)

Inactive (Rolls Up)

This example shows how volume could roll up in one Leg of a team. You're a Senior Consultant 3 at Level 5 above the Consultant who earned the volume. Starting from the bottom of the chart, you see how CV flows up and what happens below and above you.





### Leadership Match

When you are paid as a Managing Consultant 2 or higher in the month, you can receive a Leadership Match on qualified Generations.

The Leadership Match is paid on your qualified Generations' Level

### HOW GENERATIONS WORK

Your Generation 1 is the first Consultant in any Leg in your team with a Paid-as Rank of Managing Consultant 1 or higher. A Generation 2 is the next Consultant in that Leg with a Paid-as Rank of Managing Consultant 1 or higher, and so on. LEADERSHIP MATCH IS CALCULATED WORTHIST

For illustration purposes only, if the theoretical PEG Rate for the EU at the time this bonus is calculated were .90, then the Cap Per Match in local currency would be calculated as follows:

 Cap Per Match amount in US\$ is multiplied by the theoretical EU PEG Rate.

For example, the Cap Per Match for a Managing Consultant 2 would be US\$1,000 X.90 (theoretical EU PEG Rate) = €900.

MONTHLY LEADERSHIP MATCH CAN PAYOUT UP TO A MAXIMUM OF 9% OF MONTHLY GLOBAL CV.


GENERATION	1
GENERATION	2
GENERATION	3
GENERATION	4
GENERATION	
GENERATION	
GENERATION	7
CAP PER MAT	СН

When you reach the Leader level, you've shown you truly know what it takes to succeed and have the skills to help mentor and motivate others. Keep cultivating your future leaders and helping them grow and you can earn substantial bonuses for building such a strong team.

MANAGING CONSULTANT 2	MANAGING CONSULTANT 3					PRESIDENTIAL
7%	12%	15%	205	20%	20%	20%
	10%	12%	15%	20%	20%	20%
		10%	12%	15%	20%	20%
			10%	12%	15%	20%
				10%	12%	15%
					10%	12%
						12%
\$1,000	\$2,500	\$5,000	\$7,500	\$10,000	\$15,000	\$15,000

### IN PRACTICE

In this example, as a Managing Consultant 3, you earn a 12% Leadership Match on your Generation 1 Consultants and a 10% match on your Generation 2 Consultants. Qualified Generations are based on Peid-os Ranks. You c multiple Generation 1 Consultants within a Leg. The Lead Match is paid in addition to any other bonuses and comm you might already be earning





### Leadership Pool

When you are paid as an Executive Consultant 1 or higher, you earn shares of our monthly Leadership Pool. This pool is made from 4% of global monthly CV. You receive shares based on your Pakt-as Rank.

The total pool amount is divided equally by the tota number of monthly shares Consultants earn.

	SHARES
EXECUTIVE CONSULTANT 1	1
EXECUTIVE CONSULTANT 2	3
EXECUTIVE CONSULTANT 3	5
EXECUTIVE CONSULTANT 4	10
PRESIDENTIAL CONSULTANT	20

ADERSHIP POOL IS CALCULATED MONTHLY

-



### Notices

- LifeVantage Netherlands BV. is a Direct Sales/Network Marketing company with a Multi-Level Marketing compensation plan that proviflexibility and apportunity for individuals to earn extra income based upon selling apportunity to Customers.
- The focus of the LifeVentage Compensation Plan is to pay bonuses and commissions to LifeVentage Consultants based upon their product sales and the product sales of LifeVentage Consultants in their personal production team to utilize and using Contempor.
- LifeVantage products are not sold in retail stores and only licensed.
   Consultants in Good Standing are authorized to self LifeVantage products either directly from their own stock or indirectly through the company's poline shopping cost at twee-lifevantage com.
- 4. The Consultant Agreement consists of the LithVantage Compensation Plan, the LiteVantage Consultant Application and Agreement, the LiteVantage Policies and Procedures, the LiteVantage Vintual Office Agreement (Back Office Agreement, and the LiteVantage Privacy Policy and Wibble Use Agreement. The Consultant Agreement governs the contractual relationship and obligations of each LiteVantage Consultant to Hibblestone.
- A LifeVantage Consultant may not personally purchase for themse nor encourage Customers or other Consultants to purchase more inventory than each can personally consume and/or sell to their
- Consultant personally agrees that they may not any given month unless 70% of all orders from p
- 5. The Consultants sales earnings disclosed are por earnings and not net of other business expenses representative of the actual income, if any, that o will earn through the LifeVantage Compensation I earnings will depend on the Individual difference, market conditions. LifeVantage does not guarante.
- Beginning on 1 February 2024 no new Business C allowed, and all existing Business Centres, wheth will be terminated and will not be reinstated. Any
- 8. Beginning on February 1, 2024, a famil
- For Loadership Match, if after the individual caps, the monthly Leadership Match payout exceed 9% then all monthly Leadership Match earnings will b an equal percentage in order to ensure that their Match does not exceed 9% of monthly circhnic CV.

Notes	
22	

### CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Steven R. Fife, certify that:

- . I have reviewed this quarterly report on Form 10-Q of LifeVantage Corporation;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for the periods presented in this report:
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Steven R. Fife
Steven R. Fife
President and Chief Executive Officer

Date: May 2, 2024 (Principal Executive Officer)

### CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, Carl A. Aure, certify that:

- 1. I have reviewed this quarterly report on Form 10-Q of LifeVantage Corporation;
- Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Carl A. Aure
Carl A. Aure
Chief Financial Officer
(Principal Financial Officer

Date: May 2, 2024 (Principal Financial Officer)

### CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the filing of this quarterly report on Form 10-Q of LifeVantage Corporation (the "Company") for the period ended March 31, 2024, with the Securities and Exchange Commission on the date hereof (the "report"), I, Steven R. Fife, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- 1) The report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- 2) The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the report or as a separate disclosure document.

/s/ Steven R. Fife Steven R. Fife President and Chief Executive Officer

Date: May 2, 2024 (Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

### CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the filing of this quarterly report on Form 10-Q of LifeVantage Corporation (the "Company") for the period ended March 31, 2024, with the Securities and Exchange Commission on the date hereof (the "report"), I, Carl A. Aure, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- 1) The report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- 2) The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

The foregoing certification is being furnished solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the report or as a separate disclosure document.

/s/ Carl A. Aure Carl A. Aure Chief Financial Officer
Date: May 2, 2024 (Principal Financial Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.